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Abstract  
Meiosis is a unique form of cellular division that requires the use of genes normally not 
expressed in other tissues. Recently, it has been discovered that many of these meiotic genes are 
being expressed in cancer cell lines. Some of the cell lines identified follow the Alternative 
Lengthening of Telomeres (ALT) pathway as a means to extend their telomeres in the absence of 
telomerase, successfully overcoming replicative mortality. A group of meiotic genes identified 
play a role in mechanisms such as homologous recombination and DNA damage repair – 
processes essential for the ALT pathway. In an effort to better understand which meiotic genes 
are necessary and unique to the ALT mechanism, we surveyed ALT positive and ALT negative 
cancer cell lines for specific gene expression. After identifying genes of interest, we introduced 
the Auxin Induced Degradation (AID) system into the ALT positive U2OS pediatric 
osteosarcoma cell line as a method to conditionally deplete candidate proteins of interest during 
specific stages of the cell cycle.  
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Introduction 
Replicative Immortality and Telomere Function in Cancer 
 One of the major hallmarks of cancer is an ability to replicate indefinitely, thereby 
successfully overcoming replicative morality that most somatic cells eventually succumb to. 
Characterizing the processes that facilitate a somatic cell to become cancerous has proved a 
daunting task for researchers; however, the functionality of the telomeres plays a crucial role in 
determining if a cell will continue to divide. As cells undergo multiple rounds of DNA 
replication, they lose their telomeric DNA as a result of incomplete DNA synthesis. This 
functions as an endogenous mitotic clock, which eventually leads a cell to enter into replicative 
senescence and reach what is called its “Hayflick Limit” (Hayflick and Moorhead, 1961; Shay 
and Wright, 2011).  
 Telomeres contain stretches of G-rich tandemly repeated sequences of DNA located on 
the ends of every chromosome (Pickett and Reddel, 2015). Because telomeric DNA contains 
repetitive sequences, they have the capacity to form various secondary structures that physically 
prevent complete DNA replication. As a result, each round of replication leaves about 50-200 bp 
of DNA un-replicated at the 3’ end, creating what is known as the end replication problem (Levy 
et al., 1991). The majority of cancer cells contain a mutation that results in the upregulation of 
the gene coding for telomerase. This is a specialized enzyme that has reverse transcriptase 
activity accomplished through the catalytic subunit called human telomerase reverse 
transcriptase (HTERT). However, there are a small subset of cancers (10-15%) that utilize the 
Alternative Lengthening of Telomeres (ALT) pathway to extend telomeric DNA in the absence 
of telomerase.  
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The shelterin protein complex plays an important role in inhibiting initiation of DNA 
damage responses at the telomere by protecting single-stranded DNA ends from being detected 
as DNA damage. The shelterin complex consists of six core proteins – telomeric-repeat binding 
factor 1 (TRF1), TRF2, TRF1 interacting protein 2 (TIN2), protection of telomeres 1 (POT1), the 
POT1 and TIN2 interacting protein (TPP1) and the transcriptional repressor/activator protein 
(RAP1) (Figure 1; Deng et al., 2008). When telomeres become shorter due to multiple cycles of 
replication, it is more likely that they will elicit a DNA damage response as a result of ineffective 
shelterin functioning. DNA damage responses can result in a variety of events such as inaccurate 
non-homologous end joining, anaphase bridges, aneuploidy, and reactivation of telomeric DNA 
replication enzymes.  
 
Misexpression of Meiotic Genes in Cancer  
 Recently, researchers have demonstrated that multiple genes, once thought to only play a 
role in meiosis, are actually upregulated in cancer. Furthermore, many of these genes may play 
an important role in the processes necessary for cancer cells to overcome replicative mortality or 
avoid cellular senescence. To date, there have been more than 200 genes identified whose 
expression is restricted to germ cells but often reactivated and aberrantly expressed in tumor cells 
(Almeida et al., 2009). Thus, it is apparent that the processes involved in gametogenesis and 
tumorigenesis have various overlaps and similarities. Furthermore, the correlation between 
epigenetic alterations and aberrant genetic expression patterns in cancer could provide insight on 
how these genes are being controlled (Wang et al., 2016). Identification of these genes is 
advantageous because they offer an attractive target for therapy due to their lack of expression in 
tissues other than the gonads.  
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 Of the meiotic specific genes found to be aberrantly expressed in cancer, they can be 
broken down into two useful groups; those found on the X chromosome and those found on the 
autosomes. Scientists have identified that those misexpressed meiotic genes present on the X 
chromosome are most advantageous for the development of experimental cancer vaccines. The 
first antigen capable of inducing a cytotoxic T-lymphocyte response (CTL) in cancer patients 
was termed melanoma antigen-1 (MAGE-1), later discovered to be part of a multigene family. 
Using T-cell epitope cloning methods, researchers have identified two additional antigen gene 
families: BAGE and GAGE. The gene families MAGE, BAGE, and CAGE are activated in a 
wide range of cancers and have been mapped to the X chromosome (Scanlan et al, 2002). Many 
of the gene families identified on the X chromosome function as transcription factors or other 
regulatory proteins; however, the majority of them have yet to have their function understood. 
Additionally, some of the non-X chromosome gene families aberrantly expressed in cancer 
function as components that aid in the structural integrity of DNA and other cellular components 
through gametogenesis, while others function as regulatory proteins (Simpson et al., 2005).  
 Some of the meiotic specific genes identified as being aberrantly expressed in tumor cells 
are involved in processes that promote meiotic recombination. During meiosis, proteins induce 
DNA double strand breaks to facilitate homologous recombination, which is essential for 
increasing genetic diversity among gametes and facilitating proper segregation of homologous 
chromosomes during the first meiotic division. A protein structure called the synaptonemal 
complex (SC) forms between two homologous chromosomes and mediates the chromosome 
pairing and recombination (Baudat et al., 2013). Accurate recombination and synapsis between 
homologs is essential to prevent uneven segregation of chromosomes resulting in aneuploidy. 
One hallmark of cancer cells is their lack of a normal karyotype. Cancer cells tend to have 
	   	   	  
	   4	  
numerous, fragmented chromosomes that fail to segregate properly during multiple rounds of 
division. Genes whose protein products make up the SC, such as SYCP1, or those that function in 
homologous chromosome pairing and recombination during SC formation, such as SPO11, have 
been identified as being expressed in some cancer lines. SPO11 is a component of a type IIB 
topoisomerase that forms DNA double stranded breaks (DSBs) during meiosis. These DSBs are 
essential for the initiation of homologous recombination. SYCP1 proteins form the transverse 
filaments of the SC, which bridges the two homologous chromosomes together (Simpson et al., 
2005). Thus, meiotic proteins involved in chromosome structure, recombination and segregation 
are of interest in cancer, as they may be aberrantly expressed in response to, or even a source of, 
these malfunctions.  
One meiotic gene of interest that is aberrantly expressed in some cancer lines is MEIOB, 
which is also essential for meiotic recombination and exhibits 3’-5’ exonuclease activity. 
MEIOB functions by localizing to meiotic chromatin and forming a complex with SPATA22, 
which is thought to regulate its nuclease activity, and enhance the specificity of the substrate that 
MEIOB binds to (Luo et al., 2013). It has been demonstrated that the MEIOB-SPATA22 
complex plays a critical role during the development of cancer, especially lung adenocarcinoma 
(LUAD) (Wang et al., 2016). Another example is the HORMA domain protein 1 (HORMAD1), 
which is expressed in triple-negative breast cancers (TNBSs). HORMAD1 is essential for normal 
SC formation and the recruitment of ATR to un-synapsed chromatin during meiosis. In DSB 
repair, DNA end resection results in single-stranded 3’ overhangs bound by RAD51 and DMC1 
recombinases. These proteins facilitate homology search to find a primer template for new DNA 
synthesis to occur between homologs or sister chromatids (Daniel et al., 2011).  
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HORMAD1 is involved in inhibiting RAD51-dependent sister chromatid recombination 
in favor of DMC1-mediated recombination with the homologous chromosome during meiosis. 
The inhibition of RAD51 function in cancer cells promotes alternative forms of DNA repair, 
resulting in the generation of Allelic-imbalanced Copy Number Aberrations (AiCNA) (Watkins 
et al., 2015). Furthermore, DMC1 has been indicated as having increased expression in certain 
cancer lines (Kalejs et al., 2006). Thus, increased DMC1-mediated recombination in cancer may 
result in further aberrations such as translocations, insertions, or deletions. Taken together, 
meiotic specific proteins such as DMC1, HORMAD1, and SPO11 that are involved in the 
initiation of cross over events and successful resolution via HR play an important role in the 
genomic instability of cancer cells. Researchers are still working to better understand the 
function of these meiotic specific HR genes when they are aberrantly expressed in cancer cell 
lines.  
  
DNA Damage Responses and Cancer   
 After multiple cell divisions telomere functioning can become impaired, and the 
canonical DNA damage response pathway is activated. This involves p53, which facilitates a 
cascade of events leading to apoptosis or replicative senescence (Deng et al., 2008). One of the 
main proteins involved in helping to control p53 concentrations in the cell is MDM2, which 
binds to p53 and facilitates its degradation (Momand et al., 1999). When the cell senses DNA 
damage, MDM2 is inhibited, thus concentrations of p53 in the cell rise. This results in the 
activation of various downstream signaling pathways that ultimately lead to apoptosis or cellular 
senescence.  
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Continuously dividing somatic cells succumb to various sources of DNA damage 
throughout their lifespan. Some DNA damage is due to environmental factors, such as UV 
radiation, while others are intrinsic, such as errors in DNA replication. Sometimes these genetic 
insults result in single base pair mutations (Tomasetti et al., 2017). Cells have developed ways to 
detect and correct these errors, such as nucleotide excision repair (NER) and mismatch repair 
(MMR). However, sometimes DNA damage can result in single and double stranded breaks 
(SSB and DSB, respectively), which require a more specific method of detection and correction. 
The initial steps of detection involve recognition of free DNA ends by the MRE11-RAD50-
NBS1 complex (MRN complex), which activates ataxia-telangiectasia mutated (ATM). 
Activated ATM will phosphorylate substrates such as CHK2, p53, and H2AX. Phosphorylated 
H2AX (γH2AX) is recognized by MDC1, which spreads activated ATM and γH2AX over a 
large area of the chromatin (Marechal and Xou, 2013). This process creates a platform for 
subsequent reactions to take place to fix the SSB or DSB. The most severe form of DNA damage 
is the DSB, and it is an essential part of the ALT mechanism.  
Two major ways cells repair DSBs is through homologous recombination (HR) and non-
homologous end-joining (NHEJ). In HR, DNA is first resected to create a 3’ single-stranded 
overhang before a homologous chromosome is used as a DNA template to synthesize the missing 
nucleotides, resulting in more accurate DSB resolution. NHEJ, however, is more error prone and 
involves DNA ligase IV functioning to re-ligate the two free DNA ends together without 
resection or a homologous template (Polo and Jackson, 2011). If nucleotides are lost during DSB 
formation they are not accounted for during NHEJ, which could result in point mutations. Both 
HR and NHEJ indicate some level of genomic instability occurring in the cell, and proliferating 
cells demonstrate the highest propensity for HR (Bishop and Schiestl, 2002).  
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In meiosis, HR facilitates exchange of genetic information between maternal and paternal 
alleles, thus generating genetic diversity. Furthermore, it facilitates accurate segregation of 
homologous chromosomes during meiosis I by forming chiasmata, thus ensuring that aneuploidy 
does not occur (Filippo et al., 2008). In cancer, HR machinery is highly active as the DNA of 
cancer cells is fragmented, full of damage, and cells are rapidly dividing. In rapidly dividing cell 
populations, such as those found in the intestine and uterine epithelia, HR could be a source of 
genetic alterations and potentially result in a loss of heterozygosity or cause aberrant genomic 
rearrangements that may eventually lead to carcinogenesis (Bishop and Schiestl, 2002). 
If DNA damage occurs and is not successfully fixed, there are a number of problems that 
could result. If the damage incurred results in a non-functional tumor suppressor protein, for 
example, the cell could lack the ability to turn off mitogenic signals resulting in continued cell 
divisions. Likewise, if the damage results in an overactive oncogenic protein, this cell could 
continue proliferating as the signal produces positive feedback on mitogenic pathways. 
Furthermore, if the damage occurs at the telomeres, the cell may upregulate telomerase or the 
ALT pathway. This could potentially enhance telomere elongation and prepare the cell for 
multiple cellular divisions. Many cancer promoting genes are affected as a result of DNA 
damaging events, resulting in faulty mitogenic pathways or the inhibition of apoptosis or cellular 
senescence.  
 
The ALT Phenotype and Homologous Recombination  
The ALT phenotype is characterized by the presence of large specialized ALT-associated 
promyelocytic leukaemia (PML) nuclear bodies (APBs), which co-localize with telomeric DNA 
and other telomere associated proteins (Muntoni and Reddel, 2005). APBs contain proteins that 
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are involved in DNA recombination and DNA repair, which is a vital part of the ALT 
mechanism. Furthermore, APBs contain telomere specific proteins such as TRF1 and TRF2, 
which are part of the shelterin complex. This complex helps to maintain the structural integrity of 
the telomere by preventing the telomere from eliciting a DNA damage response or illegitimate 
nucleolytic degradation (Deng et al., 2008). In addition, the ALT phenotype can be identified by 
large amounts of extrachromosomal telomeric DNA, which can exist in various forms, including 
predominantly double-stranded telomeric circles (t-circles), partially single-stranded circles (C-
circles or G-circles), linear double –stranded DNA, and “t-complex” DNA that contain 
abnormal, branched structures (Cesare and Reddel, 2010).  
 The processes that facilitate ALT are usually results in telomeric DNA that is not 
sequentially or structurally the same as normal telomeres. Normal telomeric DNA contain 
stretches of G-rich tandemly repeated sequences. These sequences provide the telomeric DNA 
with the capacity to form various secondary structures, such as G-quadraplexes and T-loops, as 
well as other hypothetical structures such as triple helices, four-way junctions, and D-loops 
(Gilson and Geli, 2007). These structures form physical barriers for replication machinery to 
combat, thus replication at the telomeres is incomplete, resulting in about 50-200 bp of DNA un-
replicated at the 3’ end during each round of cellular division. Because telomeric DNA contains 
a repetitive sequence, when ALT positive cells extend their telomeres using HR, the invading 
strand may not always match up perfectly as a template to allow for the canonical TTAGGG 
sequence to be repeated accurately. This process results in telomeric DNA becoming 
interspersed with variable, non-canonical sequences, which is a hallmark of the ALT phenotype. 
As a result, telomeric binding proteins, like those in the shelterin complex, are not able to bind 
efficiently to telomeres and therefore lose their function (Bechter et al., 2004).  
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The HR repair mechanism is essential for the ALT pathway. A collection of core genes, 
known as the RAD52 epistasis group, is required for HR. The protein products of this group in 
humans includes the MRN complex – consisting of MRE11, RAD50, and NBS1 – BRCA2, 
RAD52, RAD54, RAD54B, RAD51B-RAD51C complex, RAD51D-XRCC2 complex, and the 
RAD51C-XRCC3 complex (Filippo et al., 2008). In addition, the expression of a variety of other 
accessory genes are required for ALT – some are also expressed in meiosis. Whether 
recombination is occurring in meiosis or as part of the ALT pathway, the process starts with a 
DSB followed by end resection and strand invasion on a DNA template – a homologous 
chromosome in the case of homologous recombination.  
In the ALT mechanism, it is thought that a recombination-dependent replication process 
called Break Induced Repair (BIR) is necessary. This mechanism is used to repair broken 
chromosomes when a single-stranded overhang is present in DNA (Kraus et al., 2001). Single-
stranded overhangs are common in stalled replication forks, which frequently occur at telomeres 
due to the abnormal secondary structures present. When a fork collapses in a telomere, it is 
unlikely to be resolved by incoming or dormant forks, since it is thought that human telomeres 
lack replication origins.  In BIR, a D-loop is formed when the 3’-end of a single-stranded DNA 
invades a double-stranded homologous DNA segment. This invading strand then serves as a 
primer for initiation of DNA replication. The non-essential subunit of DNA polymerase delta, 
POLD3, is required for BIR and leads to conservative DNA replication (Figure 2; Roumelioti et 
al., 2016). Furthermore, the initial sensor of telomere damage that establishes DNA polymerase 
delta (through POLD3) is the proliferating cell nuclear antigen (PCNA), which is loaded by 
replication factor C (RFC). BIR at the telomeres is thought to be independent of ATM, ATR, or 
RAD51, but requires the RFC-PCNA-Pol delta axis (Dilley et al., 2016).  
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The SMC5/6 complex promotes the repair of DNA DSBs through using HR, and in ALT 
positive cells, it is required for telomeric DNA to be included in APBs (Amorim et al., 2016). 
Furthermore, the SUMO ligase MMS21, part of the SMC5/6 complex, is required for APB 
formation through stimulating the SUMOylation of various subunits of the shelterin complex 
(Potts & Yu, 2007). Another important meiotic protein complex thought to be misexpressed and 
functioning in the ALT pathway is the ATP-dependent helicase protein ATRX and its H3.3-
specific histone chaperone DAXX. This complex plays an important role in PML bodies, and 
most ALT positive cancer cells in humans have a mutated, non-functional ATRX-DAXX protein 
complex (Heaphy et al., 2011). It is not apparent that ATRX possess G-quadruplex DNA (G4-
DNA) unwinding activity, and it may overcome this obstacle indirectly by facilitating the histone 
H3.3 deposition so that DNA is maintained in a B-form conformation, or by promoting a fork 
bypass through template switching (Amorim et al., 2016). Thus, it has been suggested that a 
potential consequence of losing ATRX functioning is a higher frequency of G-quadraplexes, 
which results in more DNA damage at the telomeres. The presence of G-quadraplexes can 
promote the ALT phenotype by presenting a barrier to the replication fork, thus causing fork 
stalling, collapse, and subsequence activation of the HR mechanism as a means to repair the 
damaged DNA (Amorim et al., 2016). 
The heterogeneity within telomeric DNA, caused by BIR or other repair mechanisms, can 
create high-affinity binding sites for a group of nuclear hormone receptors (Pickett and Reddel, 
2015). A zinc finger protein known as ZNF827 has been demonstrated as being recruited to 
telomeres in ALT positive cells by these nuclear hormone receptors such as TRF and COUP-TF2 
(Conomos et al., 2014). Once ZNF827 has been recruited to the telomeres, it helps to recruit the 
Nucleosome Remodeling Deacetylase (NuRD) complex in a sequence specific manner (Lauberth 
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and Rauchman, 2006; Conomos et al., 2014).  In Drosophila, the NuRD complex, containing the 
subunit MI-2, functions to promote chromosome condensation during meiosis in oocytes 
(Nikalayevich and Ohkura, 2015). The NuRD complex contains nucleosome-remodeling and 
histone-deacetylation functions. The nucleosome remodeling function can displace shelterin, 
while the histone-deacetylation function (in conjunction with ZNF827) may play a role in 
countering histone demethylation by compacting telomeric chromatin. Once the NuRD-ZNF827 
complex is established, it can recruit proteins involved in DDR and HR (Conomos et al., 2014). 
 
Meiotic misexpression in the ALT pathway   
One of the meiotic specific complexes that is of particular interest in interacting in the 
ALT pathway is HOP2-MND1. This protein stimulated D-loop formation through interacting 
with the two recombinases RAD51 and DMC1, thus ensuring recombination between 
homologous chromosomes is favored over recombination between sister chromatids during 
meiosis (Cho et al., 2014). Because HOP2-MND1 favors specific DNA molecules, it is possible 
that it increases the variety of templates available during HR for the ALT pathway to work. ALT 
positive cells have characteristics that are unique to this pathway, thus it may contain specific 
features that allow interaction between RAD51, HOP2, and MND1 (Arnoult & Karlseder, 2014). 
These interactions increase the sequence heterogeneity, which is conducive to the ALT 
phenotype. Variation in telomeric DNA sequences of ALT positive cells has been shown to be 
important for its interaction with many of the proteins involved in the ALT (Lee et al., 2014). In 
addition, HOP2-MND1 has been demonstrated as localizing to APBs on the telomeres of ALT 
positive cells, and knocking down HOP2-MND1 in these cells results in a significant reduction 
in APB formation (Cho et al., 2014).  
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Proteins involved in HR play an important role in facilitating their respective function in 
the ALT pathway. In meiosis, the protein disrupted meiotic cDNA 1 (DMC1) forms right-handed 
helical filaments on ssDNA in an ATP-dependent manner, catalyzing the pairing of homologous 
DNA and facilitating strand exchange reactions within these nucleoprotein filaments (Filippo et 
al., 2008). Likewise, the ATP dependent DNA helicase homolog HFM1 is expressed during 
meiosis and helps to facilitate successful cross-over formation during HR, which leads to the 
complete synapsis of homologous chromosomes (Pu et al., 2016). Proteins like these, which are 
known to play an important role in meiosis, are of interest in their interaction with the ALT 
mechanism and their propagation in cancer in general.  
 
Auxin Induced Degradation (AID) 
 The Auxin Induced Degradation (AID) mechanism is a tool used to quickly, 
conditionally, and reversibly deplete a protein of interest in vitro. This system is a plant specific 
mechanism and includes two parts: 1 – the SCF complex, which is an E3 ubiquitin ligase and 
consists of three proteins – SKP, CULLIN, and a variable F-BOX, and 2 – target proteins that 
harbor a specific domain/motif known as the auxin-inducible degron. In plants, this system is 
utilized as a method of depleting members of the AUX/AII family of transcription repressors 
(which all share four conserved domain/motifs) in the presence of indole-3-acetic acid (IAA or 
auxin) (Gray et al.,2001). Researchers have been able to harvest one of the AUX/AII F-BOX 
domains of the plant SCF E3 ubiquitin ligase called TIR1 and transplant it into other eukaryotes, 
as they lack the auxin response but still utilize the SCF degradation pathway. Additionally, 
researchers have identified and isolated the domain/motif of the AUX/AII protein that the TIR1 
protein binds to in the presence of auxin (Nishimura et al.,2009). Thus, this domain/motif can be 
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incorporated into a protein of interest by inserting it into the 3’ or 5’ end of the coding sequence 
for the protein; thus, in the presence of auxin, this protein will be ubiquitinated by the SCF-TIR1 
and subsequently degraded via the proteasome (Figure 3; Natsume et al., 2016).  
Auxin shows no adverse effects on cells in vitro, so utilizing these mechanisms as a 
means to conditionally deplete a protein of interest in eukaryotic cell systems is advantageous. 
This mechanism is more efficient and specific than traditional RNAi silencing and results in less 
off target effects (Jackson and Linsley, 2010). Researchers have also identified ways to enhance 
the interactions between the TIR1 protein, the SCF complex, and the AID-tagged protein of 
interest (Figure 3). The TIR1 protein derived from the plant O. sativa (osTIR1), which grows in 
a warmer environment, has been identified as working optimally around 37oC. This thermostable 
TIR1 works better for transfection of cells in culture because they grow best at 37oC. (Nishimura 
et al., 2009). Furthermore, a new mini-AID (mAID) tag is being used, which is about 47 amino 
acids long. The smaller tag on the protein decreases the likelihood that it will physically or 
functionally interfere with the normal role the protein of interest plays in the cell (Brosh et al., 
2016). In addition to enhancing the interactions between the proteins themselves, scientists have 
also enhanced the specificity of CRISPR to function in successfully inserting the osTIR1 and the 
mAID tag in their respective locations in the genome. A specific kind of CAS9 called enhanced 
specificity Streptococcus pyogenes Cas9 (eSpCAS9) has been modified to decrease off-target 
effects by attenuating mismatches between sgRNA and target DNA so they would be less 
energetically favorable (Slaymaker et. al, 2016).  
There are various methods of inserting the TIR1 protein into the genome of the host cell 
using CRISPR technology. Likewise, there are many locations within the genome for 
incorporation. One of the most successful and efficient locations in the genome to insert a 
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constitutively expressed TIR1 gene is in the adeno-associated virus integration site 1 (AAVS1) 
safe harbor locus. This site is located on chromosome 19 (position 19q13.42), and incorporation 
here will not interfere with the expression of other endogenous genes. Other loci that have been 
targeted for transgene addition are the chemokine (CC motif) receptor 5 (CCR5) and the human 
orthologue of the mouse ROSA26 locus; however, there are shortcomings to each site that may 
differ by the cell line being used (Sadelain et al., 2012). For example, if random integration 
occurs within or near a cancer-related gene it could result in oncogenesis or cells entering 
senescence, depending on what gene is interfered with. Integration within an oncogene could 
result in variable transgene expression or insertional oncogenesis (Sadelain et al., 2012). These 
variables have the potential to confound results in experiments conducted using these transgenic 
cells.  
Two major methods have been employed to integrate the CRISPR/CAS9 machinery and 
template DNA into the cell – electroporation and cationic lipid mediated transfection. 
Electroporation may result in a lower yield of successfully transfected cells as well as 
fragmented template DNA to be inserted. Cationic lipid mediated transfection is one of the most 
efficient methods, and constitutes incubating the CRISPR/CAS9 machinery and template DNA 
with liposomes, which subsequently form DNA-liposome complex. Cationic lipids consist of a 
positively charged head group bound to one or two hydrocarbon chains, which forms a micelle in 
solution. The positively charged head group binds to the negatively charged backbone of the 
nucleic acid, facilitating DNA condensation. This positively charged surface of the lipids also 
mediates fusion of the liposome-DNA complex with the negatively charged cell membrane, 
which subsequently enters the cell through endocytosis (Figure 4; ThermoFisher Scientific; 
Liang et al., 2015). This method has proven to be more efficient, simple to perform, work on a 
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wide variety of eukaryotic cells, be less toxic to cells, and have higher yields of successful 
transfection than other methods (ThermoFisher Scientific).  
 







Figure 1. The fluorescence image at the top indicates the location of a telomere within a 
chromosome. There are a variety of proteins that bind to telomeric DNA, and 
components of the shelterin complex are represented in bold. The single-stranded 
DNA overhang is able to integrate into the double-stranded portion of the telomere, 
forming T-loops with displacement loops (D-loops). The shelterin protein complex 
also plays a role in regulating the telomere extension activity of telomerase. 
 
(Figure adapted from Verdun and Karlseder, 2007).  
 
	   	   	  






Figure 2. Model for conservative DNA synthesis during BIR. If the D-loop migrates towards 
the telomere (tel) and synthesis of the lagging strand is initiated on the displaced, 
nascent strand, then both newly synthesized strands (in blue) will segregate with the 
recipient chromosome.  
Note: R-recipient strand; D-donor strand; tel-telomere end  
 
(Figure adapted from Donnianni and Symington, 2013).  
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Figure 3. In this cell line, a TIR1 protein derived from the plant O. sativa (osTIR1) is being 
constitutively expressed. Using CRISPR and homology directed repair mechanisms, a mini-
version of the AID tag (mAID) is successfully inserted on the 3’ end of coding sequence for 
the target protein of interest. After transcription and translation, the target protein has the 
mAID tag on it and is recognized by the osTIR1 F-BOX domain of the SCF ubiquitin ligase 
and subsequently degraded via the proteasome.  
 
(Figure adapted from Natsume, T. et al., 2016).  
 
	   	   	  















Figure 4. Mechanism of cationic-lipid mediated delivery. First, the DNA is incubated with the 
cationic lipid transfection reagent, forming DNA-cationic liposome complexes. The positively 
charged surface of the liposomes binds the negatively charged backbone of the nucleic acid, 
and also facilitated binding to the negatively charged surface of the cell. The nucleic acid is 
subsequently taken up by the cell via endocytosis.  
 
(Figure adapted from ThermoFisher Scientific).  
 
	   	   	  
	   19	  
Materials and Methods 
 
Cell Lines for Protein Isolates 
 Protein isolates for this project were provided by Dr. Alan Meeker’s lab. 23 different 
ALT positive and ALT negative cell lines derived from various tissue were used analyzed. In 
Table 1 below, the cell lines used in our protein isolate analysis are presented, organized by 
tissue origin and ALT phenotype:  
Table 1. Cell lines used in protein analysis 
 ALT Positive ALT Negative Non-Immortalized 
SV-Immortalized 
(Fibroblast) 
•   GM847 •   VA13  
hTERT-
Immortalized 
 •   BJ-TERT  
Osteosarcoma •   U2OS 
•   SAOS2 
•   MG63  
•   SJSA1 
 
Pediatric Glioma •   1118  
•   SJ-GBM2 
•   KNS42 
•   SF188 












ATRX Isogenics  •   U251 
•   U251 ATRX-/- M 
•   ATRX -/- Q 
•   MOG 
•   MOG ATRX-/- A 
•   MOG ATRX-/- I 
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Cell Culture Conditions 
 In addition to obtaining and analyzing protein isolates from these cell lines, we also 
obtained frozen cell suspensions of the U2OS and SAOS2 cell lines from Dr. Alan Meeker’s lab 
for culture. Both U2OS and SAOS2 cells were cultured in complete growth media (CGM) – 
DMEM supplemented with 10% heat inactivated FBS and 1% pen/strep – and incubated at 37ºC, 
5% CO2 in filtered cell culture vessels. U2OS cells were passaged at a sub-cultivation ratio of 
1:3 every 3 days while SAOS2 cells were passaged at a sub-cultivation ratio of 1:5 every 5 days; 
at this point the cells reached sub-confluence. To passage, cells were first washed twice with 1 X 
PBS and then incubated in 0.25% Trypsin-EDTA for 1 minute at 37ºC to facilitate detachment of 
cells from the cell culture vessel surface. The Trypsin-EDTA was inactivated by adding 2 
volumes CGM. After quenching, the cells were centrifuged at 200xg for 3 minutes. U2OS cells 
were re-suspended in 6mL CGM, with 2mL being plated in a cell culture vessel with equal 
surface area as the original, resulting in a subcultivation ratio of 1:3. Likewise, SAOS2 cells 
were re-suspended in 10mL CGM, with 2mL being plated in a cell culture vessel with equal 
surface area as the original, resulting in a subcultivation ratio of 1:5.  
 
Protein Isolation and quantification  
 For western blot analysis, cells were taken from one T-75 culture flask at 80% 
confluence. Cells were collected using trypsin-EDTA detachment methods previously described. 
Cells were centrifuged at 200xg for 3 minutes followed by aspiration of the supernatant. 
Following, cells were re-suspended in 1X PBS and subsequently centrifuged again at 200xg for 3 
minutes. This wash step was performed one more time before re-suspending cells in RIPA buffer 
(Santa Cruz) supplemented with 20 µL/1mL Protease Inhibitor (Roche). Cells were left rocking 
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at 4ºC for 20 minutes. The solution was vortexed three times for 5 seconds each and left rocking 
at 4ºC for an additional 30 minutes. To disassociate proteins from DNA and other cellular 
components, lysates were sonicated (Bioruptor sonication system) at high intensity for 5 minutes 
with 30 second on/off intervals. Finally, cell lysates were centrifuged at 10,000rpm for 10 
minutes and the supernatant was saved as the protein isolate.  
 The concentration of protein in each sample was quantified using the bicinchoninic acid 
(BCA) assay and normalized to allow for band intensity to be compared on a western blot. In the 
BCA assay, peptide bonds reduce Cu2+ ions to Cu+ in a temperature dependent manner. Two 
molecules of bicinchoninic acid subsequently chelate with each Cu+ ion, which forms a solution 
that strongly absorbs light at 562nm (Thermo Scientific). Subsequently, protein samples were 
compared against a standard curve using bovine serum albumin (BSA) as the standard. The stock 
concentration of BSA was 2000µg/µL and the standard curve was built by performing a serial 
dilution down to 125µg/µL. After the concentration of each protein sample was determined, 
samples were subsequently diluted to the same concentration (2.3µg/µL). 20µL of each quantized 
sample was added to 20µL of 2x running buffer supplemented 1:20 with ß-mercaptaethanol and 
incubated at 95ºC for 5 minutes.  
 The optimal protein concentration of 2.3µg/µL was determined by running a protein 
gradient concentration experiment. At a concentration of 2.3µg/µL, 40µg of protein is present in 
17.5µL. After adding equal amounts of running buffer, the volume of 35µL contained 40µg of 
protein. Protein isolates of BJ-TERT and VA-13 underwent a serial dilution, so that 45, 40, 35, 
and 30µg were added to separate wells of a 4-5% gradient polyacrylamide gel (figure 5). The gel 
was subsequently electrophoresed at 100V to separate proteins based on size. The gel was then 
transferred to a PVDF membrane using the TransBlot Turbo system and HFM1 was stained for 
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along. HFM1 should be expressed at very low concentrations in these cells, since it is a meiotic 
specific protein. Thus, by doing this protein concentration experiment and staining for HFM1, 
other proteins that may be expressed at higher concentrations should also be detected. The results 









Figure 5. Serial dilution protocol used for protein gradient experiment. 
 
	   	   	  




Western Blot Analysis  
 Protein samples were added to a 4-15% polyacrylamide gradient, pre-cast SDS-PAGE gel 
at a quantity of 40µg/well and subsequently electrophoresed at 100V to separate proteins based 
on size. Separated proteins were then transferred from the gel to a PVDF membrane using the 
TransBlot turbo system. After transfer, PVDF membranes were blocked in sterile filtered 3% 
bovine serum albumin (BSA) in 0.2% Tween20-PBS (PBS-T) (BSA-T) overnight at 4ºC. Both 
primary and secondary antibodies were diluted in 3% BSA-T to their appropriate concentration 
(Table 2). The membrane was incubated in primary antibody for 2 hours at room temperature 
(RT) and then washed 2 times 15 minutes each with 0.2% PBS-Tween20 (PBS-T) at RT. The 
membrane was then incubated in its respective secondary antibody conjugated to horse radish 
 
Figure 6. Results for protein gradient experiment. The top lane is HFM1, while the bottom lane is 
Tubulin. The middle lane, labeled mouse testis (25µg), was used as a control. 40µg per well 
was chosen because it was the lowest concentration that showed a clear result for both BJ-
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peroxidase for 1 hour at RT and subsequently washed 1 time 15 minutes followed by 2 times 5 
minutes in PBS-T. Finally, one last 5-minute wash in 1 X PBS was performed before 
immediately imaging using enhanced chemi-luminescense (ECL). 
  Membranes were incubated in the 1:1 mixture of clarity ECL substrates (Bio-Rad) for 2 
minutes in the dark at RT before being transferred to a plastic paper cover slip and imaged using 
the Syngene SR5 system. The optimal exposure time was determined by setting the system to 
take images at various time points, such as 10, 20, 40, 60, and 90 minutes of exposure time. The 
images were then compared to determine the optimal exposure time for each western blot. This 
time varied between a few minutes to up to over an hour depending on the sensitivity of the 
antibody, specificity of the antibody, or prevalence of the specific protein of interest in the cell.  
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Primary Antibody Mouse α DMC1 Thermo: MA1-20220 37.8 1:1000 
 Mouse α HFM1 Santa Cruz: SC-
514597 
162.6 1:500 
 Rabbit α HOP2 Novus: NBP1-92301 24.7 1:200 
 Rabbit α 
HORMAD2 
Abcam: AB106256 34 1:500 
 Mouse α NSE2 Abnova: H00286053-
B01 
27.9 1:200 
 Rabbit α NSE4a Sigma: HPA037459 43.7 1:100 
 Rabbit α REC8 Abcam: AB38372 67.4 1:5000 
 Mouse α Tubulin Sigma: T9026 50 1:5000 
 Rabbit α osTIR1 Kanemaki 74 1:2000 
 Rabbit α SMC5 Novus: 100-469 129 1:500 
 Rabbit α SMC6 Abcam: AB155495 126 1:500 
 Goat α SYCE2 Santa Cruz: SC240935 19.5 1:100 
Secondary 
Antibody 
Mouse α HRP Invitrogen: R21455 N/A 1:5000 
 Rabbit α HRP Invitrogen: A10533 N/A 1:5000 
 Goat α HRP Invitrogen: R21459 N/A 1:5000 
 
Table 2. List of antibodies used in western blot procedure and analysis via ECL.   
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RT-PCR and QPCR Procedure 
 Reverse transcription PCR (RT-PCR) and Quantitative RT-PCR (Q-PCR) analysis of a 
group of meiotic genes of interest (Table 3) was performed on four different osteosarcoma cell 
lines. Each tissue type has a unique profile; therefore, we chose to analyze only osteosarcoma 
cells to avoid discrepancies between tissue types. We analyzed two ALT positive cell lines 
(U2OS and SAOS2) and two ALT negative (telomerase positive) cell lines (SJSA1 and MG63).  
 
Table 3. Meiotic genes of interest used in QPCR analysis 
1) SPO11 10) HORMAD1 19) FKBP6 28) MEIOB 
2) DMC1 11) HORMAD2 20) HFM1 29) SPATA22 
3) MEI1 12) SYCP1 21) MSH5 30) TERB1 
4) MND1 13) SYCP2 22) MSH4 31) MEIKIN 
5) RAD21L1 14) SYCP3 23) TEX11 32) TERB2 
6) SMC3 15) SYCE1 24) TEX12 33) MAJIN 
7) REC8 16) SYCE2 25) RNF212  
8) STAG3 17) SYCE3 26) CCNB1IP1  
9) HOP2 18) SYCP2L 27) MSN1  
 
 
UCSC Cancer Browser Screening   
 An analysis of the levels of expression of a group of meiotic genes of interest (Table 4) in 
lower grade glioma was performed using the UCSC Cancer Browser data. This analysis was 
performed using data from the TCGA Brain Lower Grade Glioma dataset. The data presented is 
	   	   	  
	   27	  
stratified by ATRX expression levels, given that ATRX is lost in most of the cancer cell lines 
that demonstrate the ALT phenotype.  
 
Table 4. Meiotic Genes of Interest used in UCSC Cancer Browser screening 
SPO11 HORMAD1 MSH4 
MEI11 HORMAD2 TEX11 
DMC1 SYCP1 TEX12 
MND1 SYCP2 RNF212 
RAD21L1 SYCP3 CCNB1LP1 
SMC3 SYCE1 MNS1 
REC8 FKBP6 SPATA22 
STAG3 HFM1  
PSMC3IP MSH5  
 
 
Plasmids used in transfection 
 Plasmids used in the transfection process were maintained in E. coli, which were 
subsequently expanded and the DNA extracted. The E. coli was grown and harvested for a 
plasmid midi-preparation to isolate the plasmid DNA for transfection. Both the donor DNA 
plasmids and the gRNA/CAS9 plasmids contained sequences necessary for replication of the 
plasmid within E. coli, such as a high-copy-number ColE1/pMB1/pBR322/pUC origin of 
replication. Furthermore, a lac operator was present, which allows the lac repressor to bind and 
inhibit transcription of the plasmid within the E. coli. A gene coding for a β-lactamase is present 
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in each plasmid, which confers resistance to ampicillin. This gene allows for cells that contain 
the construct to survive in the presence of ampicillin, therefore only bacteria containing the 
plasmid will be able to grow while those that do not will die.  
 The ALT positive U2OS and SAOS2 cells were chosen for transfection. Both cell lines 
were transfected with a plasmid containing a coding sequence for the F-box protein osTIR1 
(osTIR1-CMV-Puro) (pMK232; addgene ID: 72834; lab plasmid number: 214). This plasmid 
contains homology arms for insertion into the AAVS1 safe harbor locus between exon 1 and 
exon 2 and is inserted via the AAVS1 T2 CRISPR plasmid in pX330 (pX330; addgene 
ID:72833; lab plasmid number: 213). Once inserted, the osTIR1 gene is constitutively expressed 
using a cytomegalovirus (CMV) promoter as well as a CMV enhancer. A puromycin resistance 
cassette coding for puromycin N-acetyltransferase is also part of this plasmid, which allows for 
negative selection of successfully transfected cells (Figure 7). During transfection of this 
plasmid, the gRNA recognizes and binds to a 14bp segment in the AAVS1 locus between 
nucleotides 5482 and 5495, which is subsequently cut by CAS9 at nucleotide 5492. The new 
osTIR1 DNA donor construct is then inserted via homologous recombination.   
 After single cell cloning, U2OS-osTIR1 clone 3 cells were chosen for subsequent 
transfection of the SMC5-mAID construct. This construct was created using a plasmid 
containing mAID-Hygro (pMK287; addgene ID: 72825; lab plasmid number: 207). The donor 
plasmid for the SMC5-mAID targeting contains a coding sequence for the mAID protein located 
at the 3’ end of the coding sequence for the SMC5 protein, adjacent to exon 25. Two guide 
RNA’s specific for the C-terminus of the SMC5 locus, both designed using the pX330 plasmid 
(lab plasmid numbers: 221 and 222), were used for successful integration of the donor sequence. 
The endogenous promotor for SMC5 is used to drive transcription of the SMC5-mAID protein. 
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This donor plasmid also contains a coding sequence for an aminoglycoside phosphotransferase, 
which inactivates hygromycin and thus confers resistance. The expression of this cassette is 
driven by the mouse phosphoglycerate kinase 1 promoter, and the coding sequence is 
downstream of the coding sequence for the SMC5-mAID protein (Figure 8).  
 In addition to transfection of the SMC5-mAID, SMC6-mAID was also transfected into 
U2OS-osTIR1 Clone 3 cells. The donor plasmid used for this transfection was a kind gift from 
Dr. Andrew Holland’s lab (lab plasmid number 227). Two guide RNA’s specific for the C-
terminus of the SMC6 locus, both designed using the pX330 plasmid (lab plasmid numbers: 225 
and 226), were used for successful integration of the donor sequence. Three variations of the 
donor construct were used: an undigested, circular DNA donor construct, a single KPN1 digested 
linear donor construct, and a double KPN1 and FSE1 digested donor construct (Figure 9). The 
latter digestion resulted in a donor construct including the homology arms and what is located in 
between. This was isolated from the DNA remaining after digestion using a PCR cleanup kit.  
 The donor plasmid for the SMC6-mAID targeting contains a coding sequence for the 
mAID protein located at the 3’ end of the coding sequence for the SMC6 protein. Directly 
adjacent to the mAID coding region is a FLAG tag coding sequence, which is subsequently 
bound to the SMC6-mAID protein after it is transcribed and translated. Downstream of the 
coding sequence for the SMC6-mAID protein, a coding sequence for an aminoglycoside 
phosphotransferase is present, which confers resistance to neomycin, kanamycin, and Geneticin 
(G418). Past the 3’ homology arm for SMC6 is a coding sequence for another aminoglycoside 
phosphotransferase that confers resistance to Hygromycin. Past the origin of replication that is 
used to replicate this plasmid in E. coli is a coding region for β-lactamase, which confers 
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resistance to ampicillin and allows for negative selection during expansion of E. coli containing 




Figure 7. Donor construct for insertion of osTIR1 into the AAVS1 safe harbor locus. This construct 
includes the coding sequence for the F-Box protein osTIR1. Additionally, a puromycin 
resistance cassette is located within the sequence to be inserted, thus allowing for negative 
selection of successfully transfected cells.  
 
 
Figure 8. Donor construct for insertion of SMC5-mAID. This construct includes a coding sequence 
for the mAID protein located on the 3’ end of the coding sequence for the SMC5 protein, 
directly adjacent to exon 25. This construct includes a hygromycin resistance cassette, which 
allows for negative selection of successfully transfected cells.  
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Transfection of the AID system   
 Cells were plated on 6-well plates 2 days before transfection, and allowed to grow to 60-
70% confluence. Immediately before cells were transfected, media was aspirated from the cells 
and fresh CGM was added. Cells were transfected using the LipoJet in Vitro DNA and siRINA 
Transfection Kit (Ver. II) (SignaGen Laboratories). The liposomes used in this transfection kit 
are formulated from novel fluorinated cationic lipids, and this is one of the most efficient 
transfection kits on the market. A working solution of the LipoJet transfection buffer was 
prepared by diluting the 5X concentrated stock solution to 1X. For preparation of the LipoJet-
 
Figure 9. Donor construct for insertion of SMC6-mAID. This construct includes a coding sequence 
for the mAID protein located on the 3’ end of the coding sequence for the SMC5 protein. 
This construct includes a neomycin resistance cassette, which allows for negative selection of 
successfully transfected cells using Geneticin (G418).  
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DNA complexes, a total of 1ug of DNA was added to 200uL of the 1X LipoJet transfection 
buffer for each well of the 6-well plate to be transfected. This 1ug of DNA included 0.3ug of the 
Cas9 and guide RNA(s) (gRNA) and 0.7ug of the donor DNA.  
 This mixture was vortexed briefly before 4uL of the LipoJet reagent, including the 
liposomes, was added. This solution was then incubated at room temperature for 10 minutes to 
allow the LipoJet-DNA complexes to form. 200uL of this solution was added to each well of the 
6-well plate and swirled gently to homogenize the solution. Cells were then incubated at 37ºC, 
5% CO2 for 24 hours. After 24 hours, media containing the transfection reagent was aspirated 
and fresh CGM was added. Subsequently, the appropriate antibiotics were administered to the 
media to negatively select for cells that were successfully transfected.  
 
Single Cell Cloning and Selection  
 After cells were transfected with osTIR1 in 6-well plates, antibiotics were introduced into 
the media for negative selection. Cells were incubated in CGM supplemented with 1µg/mL of 
puromycin, and this antibiotic containing media was refreshed every other day. Puromycin was 
used as a selective antibiotic because the osTIR1 construct contains a gene coding for puromycin 
N-acetyltransferase, which inactivates puromycin within the cell. Thus, cells containing this 
construct will survive in the presence of puromycin, while those that do not will die. The optimal 
concentration of puromycin was determined by incubating wild type (WT) cells not transfected 
with the osTIR1 construct in 0.5µg/mL, 1µg/mL, and 1.5µg/mL puromycin until there was 
complete cell death. 1µg/mL puromycin was determined as being completely toxic to WT cells 
and there was complete cell death after 5 days of incubation, while 1.5µg/mL puromycin resulted 
in complete cell death after just 2 days. Thus, 1.5µg/mL puromycin was too toxic, and may result 
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in a lower yield of osTIR1 transfected cells during selection. As a control, WT cells were 
incubated with 1µg/mL puromycin alongside osTIR1 transfected cells undergoing selection. 
After 5 days of incubation with 1µg/mL puromycin, cells successfully transfected with the 
osTIR1 construct remained, while those not transfected were killed off. Cells were then 
transferred to a T-25 filtered culture flask and incubated with 1µg/mL puromycin for an 
additional 3 days to be sure there were no un-transfected cells still present.  
 After cells transfected with osTIR1 were selected for using puromycin, single cell clones 
were obtained. Cells were collected using trypsin-EDTA detachment methods previously 
described. Cells were then collected by spinning them down at 200xg for 3 min and re-suspended 
in 5mL CGM without antibiotics. The concentration of cells was calculated using a 
hemocytometer and an aliquot of the cell suspension was prepared at a concentration of 
1cell/100µL. This suspension was then plated into a 96-well plate using a multichannel pipette. 
Afterwards, the plates were incubated at 37ºC, 5% CO2 for 3-5 hours to allow cells to settle to 
the bottom of the plate. Each well of the 96-well plate was analyzed, and wells that had only one 
cell successfully plated in them were marked. The cell concentration of 1cell/100µL was used 
because each well of a 96-well plate holds 200µL. Thus, cells were plated at 0.5 cells/well, 
which provided the best chance that out of 96 wells, some wells would be successfully plated 
with only one cell in them.  
 Cells successfully plated at one cell per well were allowed to proliferate until they 
became sub-confluent. Cells were then collected using trypsin-EDTA detachment methods 
previously described. After quenching the trypsin, cells were immediately transferred to one well 
of a 24-well plate, and allowed to proliferate until they became sub-confluent. This process 
continued, transferring cells next to a 12-well plate, 6-well plate, and finally a T-25 filtered cell 
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culture flask. Interestingly, the SAOS2 cell line was not proliferative after being plated as single 
cell clones and cells would enter senescence after a few rounds of division, eventually 
undergoing apoptosis. It appears these cells need to be in groups to thrive, possibly due to growth 
factors secreted from neighboring cells. Thus, U2OS cells were used for single cell cloning and 
subsequent transfections. U2OS-osTIR1 singe cell clones were harvested and their protein 
extracted following the methods previously described.  
 During expansion, the morphology and rate of proliferation were observed and compared 
to the WT U2OS cell line. Transfected U2OS single cell clones that most closely resembled the 
WT cell line during expansion and most robustly expressed the osTIR1 protein were chosen for 
subsequent transfection of mAID. U2OS Clone 3 was picked for subsequent transfection of the 
SMC5-mAID construct. Cell successfully transfected with the SMC5-mAID construct were 
selected for using hygromycin as a selective antibiotic, and the antibiotic containing media was 
refreshed every other day. The SMC5-mAID construct contains a coding region for an 
aminoglycoside phosphotransferase. This protein is an enzyme that catalyzes the transfer of a 
phosphate from ATP to an aminoglycoside such as hygromycin. Thus, this enzyme inactivates 
hygromycin, and cells successfully transfected will confer resistance to this antibiotic. The 
optimal concentration of hygromycin was determined by incubating U2OS-osTIR1 Clone 3 cells 
not transfected with the SMC5-mAID construct in 150µg/mL, 200µg/mL, and 250µg/mL 
hygromycin until there was complete cell death.  
 200µg/mL hygromycin was determined as being sufficiently toxic to U2OS-osTIR1 
Clone 3 cells and there was complete cell death after 9 days of incubation, while 250µg/mL 
hygromycin resulted in complete cell death after just 6 days. Additionally, 150µg/mL 
hygromycin resulted in complete cell death after 11 days of incubation. As a control, U2OS-
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osTIR1 Clone 3 cells were incubated with 200µg/mL hygromycin alongside SMC5-mAID 
transfected U2OS-osTIR1 Clone 3 cells undergoing selection. After 9 days of incubation with 
200µg/mL hygromycin, cells successfully transfected with the osTIR1 construct remained, while 
those not transfected were killed off. Cells were then transferred to a T-25 filtered culture flask 
and incubated with 200µg/mL hygromycin for an additional 3 days to be sure there were no un-
transfected cells still present. After successfully transfected cells were selected for using 
hygromycin, single cell clones were obtained using the same method described previously.  
 Successfully transfected U2OS-osTIR1 clone 3 cells were also used to transfect the 
SMC6-mAID construct. U2OS-osTIR1 cells successfully transfected with the SMC6-mAID 
construct were selected for using Genticin (G418). The SMC6-mAID construct contains a coding 
sequence for an aminoglycoside phosphotransferase, which inactivates G418. This 
aminoglycoside phosphotransferase also confers resistance to kanamycin and neomycin, and it is 
called a neo cassette. The optimal concentration of G418 was determined by incubating U2OS-
osTIR1 Clone 3 cells not transfected with the SMC6-mAID construct in 200µg/mL, 400µg/mL, 
and 600µg/mL G418 until there was complete cell death. In wells containing 400µg/mL G418, 
cells died after 10 days, while cells incubated with 600µg/mL G418 died after 9 days. 
 Additionally, cells incubated with 200µg/mL G418 died after 11 days. 400µg/mL was 
chosen as the optimal concentration of G418 to use for selection. As a control, U2OS Clone 3 
cells were incubated with 400µg/mL G418 alongside SMC6-mAID transfected U2OS Clone 3 
cells undergoing selection. After 10 days of incubation with 400µg/mL G418, cells successfully 
transfected with the osTIR1 construct remained, while those not transfected were killed off. Cells 
were then transferred to a T-25 filtered culture flask and incubated with 400µg/mL G418 for an 
additional 3 days to be sure there were no un-transfected cells still present. After successfully 
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transfected cells were selected for using G418, single cell clones were obtained using the same 





RT-PCR and Q-PCR DATA 
 RT-PCR and Q-PCR data for the ALT (+) and ALT (-) osteosarcoma cell lines assessed 
is displayed below. Each tissue type has a unique profile; therefore, we chose to analyze only 
osteosarcoma cells to avoid discrepancies between tissue types. The gels displaying RT-PCR 
results using testis as a control are displayed below (Figure 10 & 11). Each lane number, primer 
sequence, and expected product size that correspond to the testis control gels in Figure 10 and 11 
are displayed in table 5 and 6, respectively. The RT-PCR results for ALT positive cell lines 
(U2OS and SAOS2) and ALT negative cell lines (SJSA1 and MG63) are displayed in Figure 12 
and 13, respectively. The Q-PCR data for the ALT positive cell lines (U2OS and SAOS2) and 
ALT negative cell lines (SJSA1 and MG63) are displayed in Figure 14 and Figure 15, 
respectively. The average threshold cycle (Ct) is plotted for each gene that was tested, and those 
genes that have no bars indicate that no mRNA was found. The threshold cycle is the cycle 
during the PCR reaction at which the quantity of DNA has reached a standard threshold that is 
the same for all samples. Thus, a higher threshold cycle corresponds to a higher number of PCR 
cycles required to reach the threshold, and a lower initial quantity of cDNA for the specific gene 
present. A lower concentration of mRNA in the cell for a specific gene of interest means there 
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will be less cDNA to start with during Q-PCR and it will take more PCR cycles to reach the 
threshold, resulting in a higher threshold cycle.   
 Genes that were found to not be expressed in the RT-PCR analysis correlate closely to 
genes not expressed in the Q-PCR analysis, with a few exceptions. In the RT-PCR results, it was 
observed that there was not a band corresponding to the correct band size for the amplification 
products for genes SYCP2L2 and MSH4 in the ALT (+) U2OS cell line; however, there was 
mRNA found for these genes in the U2OS cell line according to the Q-PCR results. Interestingly, 
these two genes had the highest Ct values out of all genes found to be expressed in the U2OS cell 
line, meaning they had the lowest level of expression. This was also true for the genes 
HORMAD2, TEX11, TEX12, and MAJIN in the ALT (-) cell line MG63. There was not a band 
corresponding to the correct band size for the amplification products for these genes; however, 
they were indicated as being expressed in the Q-PCR results.  
 There were similarities and differences in which genes were observed in the Q-PCR data 
as being expressed between the ALT (+) and ALT (-) cells (Table 8). There was a larger group of 
genes not expressed in both ALT (+) cell lines analyzed than there were in the ALT (-) cell lines; 
thus, there was more meiotic gene expression in ALT (-) cells. Interestingly, all genes not 
expressed in the ALT (-) cell lines assessed are also not expressed in the ALT (+) cell lines 
assessed, except for TERB1. The ALT (+) U2OS cell line we assessed expressed TERB1, while 
both ALT (-) cell lines we assessed do not. Within the two ALT (+) cell lines we assessed, some 
genes were expressed in one cell line but not expressed in the other. In the two ALT (+) cell lines 
we assessed, there were 5 genes that were expressed in the U2OS cell line, but not expressed in 
the SAOS2 cell line: MEI1, HORMAD1, SYCE1, TEX12, and TERB1. Furthermore, there was 
only one gene that was expressed in the SAOS2 cell line but not expressed in the U2OS cell line: 
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MEIOB. These discrepancies were also true between the two ALT (-) cell lines we assessed. 
There were 4 genes that were expressed in the SJSA1 cell line but not in the MG63 cell line: 
RAD21L1, STAG3, SYCE3, and SYCP2L. Additionally, there were 5 genes that were expressed in 
the MG63 cell line but not in the SJSA1 cell line: HORMAD2, HFM1, TEX11, TEX12, and 
MAJIN. There were more discrepancies between the Alt (-) cell lines than there were between the 
ALT (+) cell lines, and the U2OS cell line expressed almost all the genes that were expressed in 
the SJSA1 cell line.  
 The Q-PCR data provides relative levels of expression of each of the genes found to be 
expressed in the ALT (+) and ALT (-) cell lines we assessed. Because each round of PCR 
amplification results in twice as much DNA as was present in the last round, a reaction that has a 
threshold cycle of 2 cycles larger than another indicates there is 4 times less initial cDNA in that 
reaction. Thus, there is 4 times lower expression of that gene and an exponential relationship 
exists between the two reactions. Of the genes we found were expressed, there was varied levels 
of expression between all 4 cells assessed. Between the two ALT (+) cell lines, genes that were 
expressed in both cell lines were expressed in similar amounts, with one major exception – 
SYCP2L was expressed in much higher quantities in the SAOS2 cell line than it was in the U2OS 
cell line. The threshold cycle for SYCP2L in the SAOS2 cell line was 31.39, while the threshold 
cycle in the U2OS cell line was 36.82. This indicates there was roughly 30 times the amount of 
starting cDNA (and therefore mRNA) for the transcription of SYCP2L in the SAOS2 cell line 
compared to the U2OS cell line.  
 Similarly, between the two ALT (-) cell lines, genes that were expressed in both cell lines 
were expressed in similar amounts, with one major exception - MEIOB was expressed in much 
higher quantities in the MG63 cell line than it was in the SJSA1 cell line. The threshold cycle for 
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MEIOB in the MG63 cell line was 31.61, while the threshold cycle in the SJSA1 cell line was 
38.07. This indicates there was roughly 42 times the amount of starting cDNA (and therefore 
mRNA) for the transcription of MEIOB in the MG63 cell line compared to the SJSA1 cell line. 
Additionally, DMC1 was expressed in larger quantities in the MG63 cell line than it was in the 
SJSA1 cell line (about 10.5 times more). Genes that were found to be expressed in either one or 
both ALT (+) and ALT (-) cell lines, respectively, there were very similar levels of expression of 
each gene between the ALT (+) and ALT (-) phenotype. However, there were two genes that 
stuck out that were both expressed in higher amounts in one or both ALT (+) cell lines. 
HORMAD1 was expressed about 25 time more in the ALT (+) U2OS cell line than it was 
expressed in both the ALT (-) MG63 and SJSA1 cell lines. Additionally, MEIOB was expressed 
about 35 times more in the ALT (+) SAOS2 cell line than the average level expression between 
both ALT (-) MG63 and SJSA1 cell lines.  
 
Table 5. Primer sequence and expected product band size for Figure 10. (Note: For = forward 
primer sequence, Rev = reverse primer sequence) 
Lane # Gene Primer Sequence Produ
ct Size 
(bp) 
1 For SPO11 ACAGAGCAACACTTATGCAACC 219 
1 Rev  GCACCACAGGTACAATTCACT  
2 For DMC1 AGAAACATGGAATTAACGTGGCT 185 
2 Rev  AAATGCAGTCAAGAATCCTGGTT  
3 For MEI1 GGTCACGCAACTGGTGTCTC 163 
3 Rev  GCAACGGATAGTCTGCTCCA  
4 For MND1 TGTGAGAGGATCGGAACTTCT 163 
4 Rev  CACATCGGCCAATTTTAGCTTTC  
5 For RAD21L1 AACCAAAGCAGACCAGAAGAAA 174 
5 Rev  GAGGCTTCCAGAACTATGTTCAA  
6 For SMC3 AACATAATGTGATTGTGGGCAGA 244 
6 Rev  TCCTTTTTGGCACCAATAACTCT  
7 For REC8 TCCGCGTCTATTCTCAACAATG 172 
7 Rev  GGATCTGGAGCATCTTCTAGGG  
8 For STAG3 GCAAAACGACCACCGAAAACA 162 
8 Rev  CCACTCATCTACCAAAGACTGC  
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Table 5 (continued). Primer sequence and expected product band size for Figure 10 
9 For HOP2 CTCCCAGGATGTGTTCGGG 285 
9 Rev  GTGGTCAGGGCACTAGATAATTC  
10 For HORMAD1 AGCAACGAATCTAGCATGTTGT 185 
10 Rev  TCACCATCCTTAAAACCGGGA  
11 For HORMAD2 CTGCATCACAATACACAAGGCT 164 
11 Rev  AATGGCGTTCTCCATAAGAGC  
12 For SYCP1 CCCTTTGCATTGTTCGTACCA 87 
12 Rev  GAAAGTGGAATCGCCTCCCA  
13 For SYCP2 AGCTGCAAATACCATCAGATGAA 131 
13 Rev  CTCTGGCACAGTAACTGCTTC  
14 For SYCP3 TATTCCAGGAAATCTGGGAAGCC 232 
14 Rev  GAGCCTTGTTAATGTCAACTCCA  
15 For SYCE1 AGGTTGGCATTCGAGGAACAG 150 
15 Rev  CGCCTTGACCAGCTTCTCT  
16 For SYCE2 GTCGGGACTCTACTTCTCCTC 83 
16 Rev  TGTTGATGTTTTCGATCAGCTCC  
17 For SYCE3 ACAACATGCTGAAAATGCTGTC 228 
17 Rev  GCCTTTGCTTGGTCTCATGC  
18 For SYCP 2L AGATGAACCTCTGCTAATTCGGC 221 
18 Rev  TCACCAGGAATCCTAAGCTAAGT  
19 For FKBP6 TTCTGTTCAAACCGAACTACGC 134 
19 Rev  GAGAGCACAAAACTTGTCTGACT  
20 For HFM1 TTTGCCTGCTCACCTAGTAGT 165 
20 Rev  TCCCTTGTGCTTAATCGAGTCA  
21 For MSH5 TGGCAGGTTCTCTACAAGACT 135 
21 Rev  GAGGCTGGCGATATGGTGC  
22 For MSH4 TTCAGCACTGTCCTAATGGAGG 155 
22 Rev  TCTATCATGGCTGTCTGTTCACT  
23 For TEX11 CTGCCAGTAGTTTTGAGGTACAA 166 
23 Rev  GCCTCTTTGGCCTTATCAAGTTG  
24 For TEX12 ATGGCAAATCACCTTGTAAAGCC 85 
24 Rev  GCTGTGGACTATCTGGCACTG  
25 For RNF212 CTGGGTGTTCTGTAATCGCTG 150 
25 Rev  AAAACTGTACGACAAGGAGCTTT  
26 For CCNB1IP1 CGTGTTGGACATTAGCTCCCG 250 
26 Rev  GCGCTCCATAAGTTTCTCAGAG  
27 For MNS1 TGCGGCAACGTGAAGATTTG 175 
27 Rev  GCAGCCTGTAGCACTAATTCC  
28 For MEIOB CCTGCAACTCCTAGCAACTGT 198 
28 Rev  TGCAAGCACGTTAATAATCCTCC  
29 For SPATA22 GAGAGGGCTAGACAAAAACAGTG 204 
29 Rev  TGTTCACGCCAATACTTCATGC  
30 For TERB1 CCCACGTAGAAGACAACGACT 186 
30 Rev  TCCACAGCCTTCCGTCCTT  
31 For MEIKIN W1 GGCTTTTGCTTTCGCTCGAT 121 
31 Rev  GTGCCTCTGGACTCTCGATG  
32 For MEIKIN W2 CGGCTTGTCGAAGATTGCAG 441 
32 Rev  TGTGGTGCCTTCTCTATCGC  
33 For MEIKIN W3 ACTCCCTGTGACTTAGCCCT 441 
33 Rev  CAATCTTCGACAAGCCGTGC  
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Table 6. Primer sequence and expected product band size for Figure 11. (Note: For = forward 
primer sequence, Rev = reverse primer sequence) 
Lane # Gene Primer Sequence Product 
Size 
(bp) 
1 For SMC3 AACATAATGTGATTGTGGGCAGA 244 
1 Rev  TCCTTTTTGGCACCAATAACTCT  
2 For SMC3 W1 CTGGCCCGTGCTTTCACTAT 255 
2 Rev  CCTTTGCTGGGTCTCGATCT  
3 For SMC3 W2 CACATGCGTGGAAGTCACTG 338 
3 Rev  GGCTGACTTGGTCACCTTCC  
4 For SMC3 W3 GCTAGACCACTTCCGTCGAA 400 
4 Rev  CATAGTGAAAGCACGGGCCA  
5 For TERB2 W1 CTGCGTGCCTGCAAAAAGAA 180 
5 Rev  AATGCTTTTCTGGGCTTTTGGA 244 
6 For TERB2 W2 TCATTCTTCCTCCTGCGTGC 160 
6 Rev  TTGTGCTCTGTTGCTAGTTCAC  
7 For TERB2 W3 GTGAACTAGCAACAGAGCACA 179 
7 Rev  GTCATGTAGCTCCCCAAGGA  
8 For MAJIN W1 GAGCTGGAGGATTCTGTCCG 343 
8 Rev  TCCCTATTCTGTCCAGCCCT  
9 For MAJIN W2 AGGGCTGGACAGAATAGGGA 305 
9 Rev   GAAGAATGGCTCGGGAGGAG  
10 For MAJIN W3 TGGGAGAGAGTTTCCCACCT 247 
10 Rev  TCCCTATTCTGTCCAGCCCT  
 
 
Figure 10. RT-PCR data for a group of meiotic genes corresponding to Table 5.  
 
	   	   	  
	   42	  
 
 
Table 7. Meiotic genes of interest used in RT-PCR and Q-PCR analyses. For U2OS, SAOS2, 
and SJSA1, the last two lanes that are not numbered correspond to TBP used as a control.  
1) SPO11 10) HORMAD1 19) FKBP6 28) MEIOB 
2) DMC1 11) HORMAD2 20) HFM1 29) SPATA22 
3) MEI1 12) SYCP1 21) MSH5 30) TERB1 
4) MND1 13) SYCP2 22) MSH4 31) MEIKIN 
5) RAD21L1 14) SYCP3 23) TEX11 32) TERB2 
6) SMC3 15) SYCE1 24) TEX12 33) MAJIN 
7) REC8 16) SYCE2 25) RNF212 34) Water Control 
8) STAG3 17) SYCE3 26) CCNB1IP1  
9) HOP2 18) SYCP2L 27) MSN1  
 
Figure 11. RT-PCR data for a group of meiotic genes corresponding to Table 6. 
	   	   	  





Figure 12. RT-PCR results for the osteosarcoma cell lines U2OS (ALT+) and MG63 (ALT-). 
Each lane corresponds to a different meiotic gene of interest surveyed for (Table 7). The 
numbers for the lanes align with the numbers for each gene of interest in Table 7.   
 
	   	   	  










Figure 13. RT-PCR results for the osteosarcoma cell lines SAOS2 (ALT+) and SJSA1 (ALT-). 
Each lane represents a different meiotic gene of interest surveyed for (Table 7). The 
numbers for the lanes align with the numbers for each gene of interest in Table 7.   
 
 
Figure 14. Q-PCR data for a group of meiotic genes surveyed for in two ALT (+) cells (U2OS 
and SAOS2). The average threshold cycle (Ct) is presented for each gene. The larger the 
average threshold, the lower concentration of mRNA for each gene was found present in 
each cell.  
 
Figure 15. Q-PCR data for a group of meiotic genes surveyed for in two ALT (-) cells (SJSA1 
and MG63). The average threshold cycle (Ct) is presented for each gene. The larger the 
average threshold, the lower concentration of mRNA for each gene was found present in 
each cell.  
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Table 8. Genes not expressed in both ALT (+), both ALT (-) or not expressed in any of the 4 cell 
lines assessed.  
*Note: Yellow – not expressed in all cell lines assessed; Green – not expressed in only ALT (+) 
cell lines assessed; Blue – not expressed in only ALT (-) cell lines assessed 
Not Expressed in ALT (+) Not Expressed in ALT (-) Not Expressed in all four 
cell lines  
SPO11 SPO11 SPO11 
SYCP3 SYCP3 SYCP3 
RNF212 RNF212 RNF212 
SPATA22 SPATA22 SPATA22 
MEIKIN MEIKIN MEIKIN 
TERB2 TERB2 TERB2 
RAD21L1 TERB1  
STAG3   
HORMAD2   
SYCP1   
TEX11   
MAJIN   
 
 
Western Blot Analysis  
 Various western blots were performed to assess the level of expression of meiotic genes 
of interest (Table 9). Each western blot is displayed below (Figures 16-31) in the order they 
appear in Table 9. Many of these genes that were originally thought to be meiosis-specific 
(DMC1, HFM1, HOP2, SYCE2) were identified as being expressed at various concentrations in 
both ALT (+) and ALT (-) cancer cell lines. There does not seem to be a preference for these 
genes being expression in ALT (+) versus ALT (-) cell lines, rather, there seems to be varying 
expression in both ALT (+) and ALT (-) cell lines.  
 Interestingly, HFM1 was identified as having reduced expression in the non-
immortalized normal breast stromal cells. Originally, we thought this may have something to do 
with the non-immortalized nature of this particular cell line. Thus, we analyzed three patient 
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derived samples of non-immortalized prostate derived mesenchymal cells (Figure 20). This result 
displayed expression of HFM1 in all three samples; therefore, we concluded that the decreased 
expression of HFM1 in normal breast stroma was not due to the non-immortalized nature of this 
cell line. Normal breast stroma is a specialized form of tissue that regulates the proliferation, 
differentiation, and survival of the mammary gland (Arendt et al., 2010). Therefore, the 
downregulation of HFM1 in normal breast stroma may be due, in part, to the specific function of 
this tissue. Furthermore, DMC1 was also identified as having reduced expression in normal 
breast stroma.  DMC1 is a meiosis-specific member of the recA-like gene family of 
recombinases that stabilizes strand exchange intermediates during homologous recombination, 
while HFM1 is an ATP-dependent helicase required to form crossovers and complete synapsis of 
homologous chromosomes (Wang et al., 2014). Both DMC1 and HFM1 are meiotic specific 
genes necessary for homologous recombination; thus, the fact that they are both downregulated 
in normal breast stroma alludes to a functional explanation for this.  
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1) DMC1 3) HOP2 5) NSE2 7) REC8 9) SMC6 
2) HFM1 4) HORMAD2 6) NSE4a 8) SMC5 10) SYCE2 
 
Figure 16. Western blot analysis of DMC1indicating DMC1 indicating varying 
expression in various ALT (+) and ALT (-) cell lines, reduced expression in normal 
breast stroma and a doublet band in human testis.  
	   	   	  





Figure 17. Western blot analysis of DMC1indicating varying expression in various 
ALT (+) and ALT (-) cell lines and a doublet in human testis.  
 
Figure 18. Western blot analysis of HFM1 indicating varying expression in ALT (+) and 
ALT (-) cell lines and reduced expression in normal breast stroma.  
	   	   	  









Figure 19. Western blot analysis of HFM1 indicating varying expression in ALT (+) and 
ALT (-) cell lines. 
 
Figure 20. Western blot analysis of HFM1 indicating varying expression in ALT (+), 
ALT (-), and non-immortalized, prostate derived, mesenchymal cell lines.  
	   	   	  







Figure 21. Western blot analysis of HOP2 indicating varying expression in ALT (+) and 
ALT (-) cell lines and decreased expression in the 1118 cell line.  
Figure 22. Western blot analysis of HORMAD2 indicating decreased expression in 
various ALT (+) and ALT (-) cell lines.  
	   	   	  








Figure 23. Western blot analysis of HORMAD2 indicating decreased expression in 
various ALT (+) and ALT (-) cell lines. 
 
Figure 24. Western blot analysis of NSE2 indicating varying expression in ALT (+) and 
ALT (-) cell lines. Decreased expression was observed in the non-immortalized, prostate 
derived mesenchymal cell line as well as the BJ-TERT cell line.  
	   	   	  







Figure 25. Western blot analysis of NSE4a indicating varying expression in ALT (+) 
and ALT (-) cell lines. Indicated is decreased expression in non-immortalized, prostate 
derived mesenchymal cells, UW479, MG63, and SAOS2.  
Figure 26. Western blot analysis of REC8 indicating expression in U251 and MOG 
ATRX isogenic cell lines as well as normal breast stromal cells.  
	   	   	  






Figure 27. Western blot analysis of SMC5 expression in varying ALT (+) and ALT (-) 
cell lines. The lowest expression was observed in the BJ-TERT and 1118 cell lines.  
 
Figure 28. Western blot analysis of SMC6 in various ALT (+) and ALT (-) cell lines, 
with the most robust expression present in the SJ-GBM2 cell line.  
	   	   	  





Figure 29. Western blot analysis of SMC6 in various ALT (+) and ALT (-) cell lines, 
with the most robust expression present in the U2OS and SAOS2 cell line.  
 
Figure 30. Western blot analysis of SYCE2 in various ALT (+) and ALT (-) cell lines. A 
doublet was observed in most cell lines, with the MG63 and U2OS cell lines having the 
faintest upper band in the doublet.  
	   	   	  















Figure 31. Western blot analysis of SYCE2 in various ALT (+) and ALT (-) cell lines. A 
doublet was observed in most cell lines, with the lowest expression observed in the 
UW479 cell line.  
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Analysis of successful transfection of AID system 
 After the U2OS and SAOS2 cell lines were transfected with osTIR1 and subsequently 
selected for using puromycin, the heterogeneous population was tested for successful insertion of 
the donor construct by harvesting the cells and running a western blot using an antibody specific 
for the osTIR1 protein. If the cells were successfully transfected, the osTIR1 gene will be 
constitutively expressed under the CMV promoter, and the osTIR1 protein will be present in the 
cells. As a negative control, WT cells that were not transfected with the osTIR1 construct were 
harvested and ran alongside the transfected cells. Figure 32 indicates a band is present 
corresponding to the correct size for the osTIR1 protein in the heterogeneous population of 
U2OS cells, while there is no band present in the WT lane. Thus, it can be concluded that there 
are cells present in this heterogeneous population expressing osTIR1. In Figure 33, the same 
analysis for the heterogeneous population of osTIR1 transfected SAOS2 cells is presented. 
Likewise, there is a band present corresponding to the correct size for the osTIR1 protein, while 
there is no band present in the WT lane; thus, it can be concluded that there are cells present in 
this heterogeneous population expressing osTIR1. 
 After single cell cloning was performed on the heterogeneous population of osTIR1 
transfected U2OS cells, clones were analyzed for successful incorporation of the osTIR1 
construct. Cells were harvested and a western blot was performed using an antibody specific for 
the osTIR1 protein. The WT U2OS cell line that was not transfected with the osTIR1 construct 
was used as a negative control, while the osTIR1-transfected heterogeneous population of U2OS 
cells was used as a positive control (Figure 32). The results indicate a band present 
corresponding to the correct size for the osTIR1 protein in the osTIR1-transfected heterogeneous 
population of U2OS cells, while there was no band present in the WT U2OS cells not transfected 
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with the osTIR1 construct. Furthermore, there is a band present for Clone 3 isolated from the 
osTIR1-transfected heterogeneous U2OS cell population, indicating this clone was isolated form 
a parent cell that was successfully transfected with the osTIR1 construct.  
 The band intensity for Clone 3 appears to be stronger than the heterogeneous population, 
which is expected because the single cell clone population was derived from one cell that is 
expressing the osTIR1 construct. In the heterogeneous population, there may be cells that 
randomly incorporated the puromycin resistance portion of the osTIR1 construct; therefore, they 
survive during puromycin selection, but they do not express the osTIR1 gene. Because Clone 3 
comes from one single cell, the same quantity of protein will contain a larger concentration of 
osTIR1 in it because almost all cells are expressing the osTIR1 gene.  
 Clone 3, the isolated osTIR1-expressing U2OS cell line, was transfected with the SMC5-
mAID construct and subsequently selected for using hygromycin, single cell clones were 
obtained. These single cell clones were analyzed for successful incorporation of the SMC5-
mAID construct. Cells were harvested and a western blot performed using an antibody specific 
for the mAID tag. A DLD-1 cell line transfected with the osTIR1 and an SMC6-mAID 
constructs was used as a positive control. This DLD-1 cell line was previously confirmed as 
being successfully transfected with both the osTIR1 and SMC6-mAID constructs during an 
experiment in which auxin was added and the depletion of SMC6 was observed.  
 In the results presented below (Figure 34), a band appears where the expected size of the 
SMC6 protein (126 kDa) should be located for the DLD1 cell line, which was used as a positive 
control. However, there does not appear to be a band located where the expected size of the 
SMC5 protein (129 kDa) would be. Therefore, it does not appear that the SMC5-mAID is being 
expressed (or lack thereof) in a way that would allow for the antibody to specific for mAID to 
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bind to it and produce a band. These cells survived under hygromycin selection; thus, this 
construct could have been randomly inserted or inserted in a way that did inhibited expression of 
the SMC5-mAID gene, such as the construct being inserted in a way that obstructed the 
endogenous promotor for the SMC5 gene. Furthermore, adding the tag to the 3’ end of the coding 
sequence for the SMC5 gene could have affected its processing or folding, resulting in 
suppressed expression. To better understand the details of this result, it would be advantageous to 
run a western blot using an antibody specific for SMC5 and see if there is expression of SMC5 in 
the cell at all. Additionally, primers designed to amplify through this insert using PCR analysis 
should be employed to confirm successful integration of the SMC5-mAID construct on the 
nucleotide level. 	  
 Additionally, Clone 3, the isolated osTIR1-expressing U2OS cell line, was transfected 
with the three variations of the SMC6-mAID construct (undigested, single KPN1 digestion, and 
double KPN1 and FSE1 digestion) and subsequently selected for using G418, single cell clones 
were obtained. These single cell clones were analyzed for successful incorporation of the SMC6-
mAID construct. Cells were harvested and a western blot performed using an antibody specific 
for the mAID tag. A DLD-1 cell line transfected with the osTIR1 and an SMC6-mAID 
constructs was used as a positive control. This DLD-1 cell line was previously confirmed as 
being successfully transfected with both the osTIR1 and SMC6-mAID constructs during an 
experiment in which auxin was added and the depletion of SMC6 was observed. In the results 
presented below (Figure 35), a band appears where the expected size of the SMC6 protein (126 
kDa) should be located for the DLD1 cell line, which was used as a positive control. However, 
there does not appear to be a band located where the expected size of the SMC6 protein would be 
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in the undigested, single, or double digested constructs. The same explanations as described for 







Figure 32. Results confirming successful transfection of the U2OS heterogeneous population 
and single cell clones 1-4 with the osTIR1 construct. Clone 3 showed the most robust 
expression of osTIR1 and was used for additional transfection of SMC5-mAID and 
SMC6-mAID  
 
 Note: The faint tubulin band in the first row is believed to be an artifact, as protein was 
still present when staining for osTIR1.   
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Figure 33. Results confirming successful transfection of SAOS2 heterogeneous population of 
cells with the osTIR1 construct. The U2OS-osTIR1 heterogeneous population was used 
as a positive control, while the WT SAOS2 cells were used as a negative control since 
they have not been transfected with the osTIR1 construct.  
 
R α osTIR1 
74 kDa 
 
Figure 34. Western blot results (using an antibody specific for the mAID protein tag) for single 
cell clones of U2OS-osTIR1(clone 3)-SMC5-mAID cells. The expected band size should 
be a little larger than 129 kDa because the antibody specific for the mAID will bind the 
mAID protein, which is tagged to the SMC5 protein. The DLD1 cells that were used as a 
positive control indicate the mAID protein tag is present and appears around the same 
band size as SMC6 (126 kDa). It does not appear that the mAID protein is present where 
the expected band for the SMC5 protein would be.  
 
	   	   	  













Figure 35. Western blot results (using an antibody specific for the mAID protein tag) for single 
cell clones of U2OS-osTIR1(clone 3)-SMC6-mAID cells. Presented are results for the 
undigested, single, and double digested construct. The expected band size should be a 
little larger than 126 kDa because the antibody specific for the mAID will bind the 
mAID protein, which is tagged to the SMC6 protein. The DLD1 cells that were used as a 
positive control indicate the mAID protein tag is present and appears around the same 
band size as SMC6. It does not appear that the mAID protein is present where the 
expected band for the SMC6 protein would be.  
 
	   	   	  
	   64	  
UCSC Cancer Browser Results    
 The data below (Figure 36) represents the results from the UCSC Cancer Browser search. 
A group of meiotic genes of interest identified in Table 4 are presented, stratified by the ATRX 
expression, in lower grade glioma (LGG). Two genes were identified in this analysis as having 
varied expression, SMC3 and REC8. However, their relative expression is not substantial 





Figure 36. Meiotic gene group of interest expression stratified by ATRX expression in lower 
grade glioma (LGG).  
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Discussion  
 In the present research, a group of meiotic genes were identified and assessed that may be 
playing an important role in cancer. These genes pose an opportunity for therapeutic intervention 
due to their lack of expression in somatic tissues, other than the gonads. Some of the processes 
these genes are involved in, including homologous recombination and maintaining genomic 
structure and integrity, have been identified as playing a role in the alternative lengthening of 
telomeres pathway (Deng et al., 2008; Cesare and Reddel, 2010). The ALT pathway utilizes 
many of the same processes that are important for meiosis, and cells that follow this pathway 
extend their telomeres in the absence of telomerase as a method of successfully evading 
apoptosis and overcoming replicative mortality. In this study, expression of the group of meiotic 
genes identified were tested for in both ALT (+) and ALT (-) cells. These analyses helped to 
better understand which meiotic genes may be important for the ALT pathway.  
 We assessed the expression of a group of meiotic genes of interest in two ALT (+) and 
ALT (-) osteosarcoma cancer cell lines through RT-PCR and Q-PCR analysis. It was important 
to use osteosarcoma in all four cell lines because each tissue type has a unique profile. 
Interestingly, there were more meiotic genes found to be expressed in the ALT (-) cell lines than 
the ALT (+) cell lines assessed. Furthermore, all genes that were not expressed in the ALT (-) 
cell lines assessed were also not expressed in the ALT (+) cell lines assessed, with one exception 
– TERB1 was expressed in the ATL (+) U2OS cell line but not expressed in either of the ALT (-) 
cell lines we assessed. In the future, it would be advantageous to assess TERB1 expression in 
these various ALT (+) and ALT (-) cell lines using a western blot analysis. TERB1, a meiosis-
specific protein, is a component of the MAJIN-TERB1-TERB2 complex. This complex 
associates with telomeric proteins and promotes telomere cap exchange by helping to attach 
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telomeric DNA to the inner nuclear membrane and replace the protective cap of telomeric 
chromosomes during meiosis (UniProt). It is possible that this protein is interacting with 
telomeres in the ALT (+) U2OS cell line to extend telomeres by facilitating homolog search 
within the cell. Additional research assessing the interaction of this complex with APB’s would 
be advantageous, since APBs have been identified as facilitating homolog search with telomeres 
in ALT (+) cells (Muntoni and Reddel, 2005; Deng et al., 2008).  
 There were differences between the two ALT (+) cell lines we assessed, and some genes 
were expressed in one cell line but not in the other. It is possible that genes expressed in one 
ALT (+) cell line but not the other are not essential to the ALT mechanism. If a gene is essential 
to the ALT mechanism, then it is more likely that it would be expressed in both ALT (+) cell 
lines. There were 5 genes expressed in the ALT (+) U2OS cell line that were not expressed in the 
ALT (+) SAOS2 cell line. Additionally, there was only one gene that was expressed in the 
SAOS2 cell line but not expressed in the U2OS cell line. It appears that the U2OS cell line 
expresses many genes that may not be expressed in other ALT (+) and ALT (-) cell lines. The 
U2OS cell line was harvested from a 14-year-old female in 1964 (ATCC). As subsequent 
divisions have occurred, the cell may have become more genetically heterogeneous in nature. 
This could explain why there are so many meiotic genes expressed in the U2OS cell line that are 
not expressed in other ALT (+) or ALT (-) cell lines. Focusing on those genes that are expressed 
in U2OS but also expressed in other ALT (+) cell lines could help better characterize which 
genes are essential for the ALT mechanism.  
 Between the genes that were expressed in both ALT (+) cell lines assessed, SYCP2L was 
expressed about 30 time more in the SAOS2 cell line than it was in the U2OS cell line. The 
SAOS2 cell line could rely on SYCP2L as a means of extending its telomeres in the absence of 
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telomerase more than the U2OS cell line. SYCP2L is a part of the synaptonemal complex and 
plays an important part in homologous chromosome pairing during meiosis. Genes involved in 
homologous recombination have been identified as playing a role in the ALT mechanism (Kraus 
et al., 2001; Roumelioti et al., 2016). Therefore, this gene could be upregulated to play a part in 
the ALT mechanism. Although this gene is expressed in much higher amounts in the SAOS2 cell 
line compared to the U2OS cell line, it could be playing a part in the ALT mechanism as it is still 
expressed in both ALT positive cell lines we assessed.  
 Additionally, there were differences between the two ALT (-) cell lines we assessed. 
There were 4 meiotic genes expressed in the SJSA1 cell line but not in the MG63 cell line, and 
there were 5 meiotic genes expressed in the MG63 cell line but not in the SJSA1 cell line. There 
were more genes that differed between the two ALT (-) cell lines than those that differed 
between the two ALT (+) cell lines we assessed. Many of these meiotic genes expressed in one 
ALT (-) cell line but not the other, such as SYCE3, SYCP2L, TEX11, and TEX12, are involved in 
cross-over events during meiosis. It is possible that homologous recombination is important for 
some cells that do not follow the ALT mechanism for telomere extension. However, it does not 
seem that it is essential, as these genes were expressed in one ALT (-) cell line assessed, but not 
the other. Additionally, the ALT (+) U2OS cell line expressed almost all the genes that were 
expressed in the SJSA1 cell line. Thus, more research should be done on these meiotic genes to 
better understand which are essential for the ALT mechanism, and which are transiently 
expressed between both ALT (+) and ALT (-) cell lines.  
 The western blot analysis performed in this study indicated that there was varied 
expression of a group of meiotic genes in both ALT (+) and ALT (-) cell lines. Thus, it is 
possible that these meiotic genes play an important part in the development of cancer in general, 
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and do not favor either the ALT (+) or ALT (-) mechanism of telomere elongation. Many of the 
meiotic genes assessed in our western blot analysis play a part in meiotic recombination. 
Although recombination is an important part of the ALT mechanism, it may also play a role in 
the development of both ALT (+) and ALT (-) cancer. In our analysis, HFM1 and DMC1 both 
had suppressed expression in non-immortalized normal breast stroma cells. The stroma in normal 
breast tissue plays an important part in guiding the development of the mammary gland, and the 
downregulation of both HFM1 and DMC1 could be due to some specialized role these cells have. 
HFM1 and DMC1 are involved in meiotic recombination; thus, it is possible that these normal 
breast stroma cells undergo much less recombination. Cells that undergo high levels of 
recombination, such as gametes, do so to increase the genetic variation within their DNA. 
Therefore, it is possible that normal breast stroma cells maintain high levels of genome integrity 





  In the future, more analysis should be performed on these meiotic genes to better 
understand which genes are involved in the ALT pathway, and which of those are important for 
the development of cancer in general. In this study, there were various discrepancies between 
which genes were identified as being expressed in ATL (+) and ALT (-) cancer cell lines. RT-
PCR and Q-PCR analysis indicated that there were more variations in meiotic gene expression 
between the two ALT (-) cell lines assessed than was apparent between the two ALT (+) cell 
lines assessed. Thus, it would be advantageous to further analyze these discrepancies between 
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Alt (+) cell lines and ALT (-) cell lines to better understand which meiotic genes are important 
for the ALT pathway.  
 The introduction of the auxin induced degradation mechanism into the ALT (+) U2OS 
cell line provides a great opportunity to analyze how the cell reacts to the depletion of any gene 
of interest. This system allows the mAID-tagged protein of interest to be depleted rapidly and 
reversibly. Therefore, it would be advantageous in the future to perform experiments such as 
depleting SMC5 or SMC6 from the U2OS cells in the presence of DNA damage and assessing 
how the cell recovers in the initial stages with SMC5 or SMC6 depleted, but then re-introducing 
SMC5 or SMC6 later by removing auxin from the growth media and observing what changes. If 
SMC5/6 is playing an important role during a specific stage in the DDR, it could be observed 
easily with this system.  
  Furthermore, this system is titratable, and it is possible to partially deplete the protein of 
interest. The amount of control of variables this system provides make it advantageous over 
previous siRNA techniques of protein knock-down. Previously, it has been demonstrated that 
knockdown of the human SMC5/6 complex by RNA interference (RNAi) inhibits telomere HR 
in ALT (+) cells, resulting in telomere shortening and cells entering senescence (Potts et al., 
2007). However, the particular RNAi molecules used were later found to be subject to off target 
effects, which causes some concern with the interpretation of the data (Wu et al., 2012). 
Furthermore, in general, RNAi does not completely knock-out the protein of interest. Thus, the 
AID system in the ALT (+) U2OS cell provides an opportunity to assess the validity of these 
findings by ensuring complete depletion of the SMC5/6 complex with no off-target effects that 
could possibly confound the results.   
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 The SMC5/6 protein complex has been indicated as playing a role in the ALT 
mechanism. The SUMO E3 ligase MMS21 (also known as NSE2) is a component of the SMC5/6 
complex, and it has been indicated as having SUMOylation properties (Chung et al., 2012). 
NSE2 of the SMC5/6 complex has been indicated as playing a role in facilitating homologous 
recombination within APBs of ALT (+) cancer cells by SUMOylation components of the 
shelterin complex, such as RAP1, TIN2, TRF1 and TRF2 (Potts, 2009). SUMOylation of 
components of the shelterin complex may promote telomeres to associate with PML bodies, as 
proteins within PML bodies have a high affinity for SUMO. Knockdown of SMC5/6 in ALT (+) 
cancer cells results in decreased recombination at telomeres, shortening of telomeres, and cells 
entering senescence (Potts and Yu, 2007). Additionally, in fission yeast treated with the DNA 
damaging agent methyl methanesulfonate (MMS), there is significantly more SUMOylation of 
both SMC6 and NSE4 by the SUMO ligase function of MMS21. It has been demonstrated that 
the SMC5/6 complex localizes to telomeres in budding and fission yeast. Therefore, this suggests 
that SUMOylation of SMC5/6 by MMS21 could potentially increase the affinity of the SMC5/6 
complex to telomeres in telomerase-positive fission yeast (Potts, 2009).  
 Additionally, it has been speculated that various other proteins, such as components of 
the NuRD-ZNF827 complex, undergo SUMOylation within the APBs (Conomos et al., 2014). 
Thus, the SMC5/6 complex plays an important role in SUMOylation events required for the ALT 
mechanism and the formation and subsequent maintenance of APBs associated with telomeres in 
ALT positive cells. In this study, SMC5 and SMC6 were independently tagged with the mAID 
tag in the U2OS cell line and the AID system introduced. Further studies utilizing the AID 
mechanism to deplete SMC5 and SMC6 independently in the ALT (+) U2OS cell line should be 
performed in the future to assess how a lack of SUMOylation within the APBs affects the 
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accumulation of APBs and subsequently the ALT mechanism. Using the AID mechanism in 
human ALT (+) U2OS cells provides an opportunity to further elucidate studies that have only 
been conducted on yeast and expand our understanding of how the SMC5/6 complex is 
functioning in the ALT mechanism in humans.  
 Additionally, the progression of ALT (+) cell through the cell cycle may rely on the 
functions of the SMC5/6 complex. Therefore, it would be advantageous to conduct experiments 
with cell synchronization, and test the effects of cell cycle progression in the presence or absence 
of SMC5 or SMC6. Experiments such as synchronizing cells at the G2/M stage of the cell cycle 
using nocodazole, then releasing in the presence or absence of the SMC5/6 complex using the 
AID system could help gain a better understanding of how the SMC5/6 complex is functioning 
during this stage of the cell cycle. Additionally, cells could also be halted at the G1/S stage of the 
cell cycle using a thymidine block. SMC5/6 has been indicated as playing a role in the collapse 
of replication forks, and thymidine induces replication fork collapse (Roy et al., 2015). At 
telomeres, replication forks commonly collapse due to the irregular secondary structures that 
form, causing single-stranded overhangs. The BIR mechanism is used to repair broken 
chromosomes when a single-stranded overhang is present in DNA and plays an important part in 
the ALT mechanism (Kraus et al., 2001). Thus, the AID system in the ALT (+) U2OS cell line 
can be used to better understand the role of the SMC5/6 complex in BIR and the ALT 
mechanism during specific stages of the cell cycle.  
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o   Dates: 10/2015-6/2016 
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o   Organization Name: Johns Hopkins School of Public Health (JHSPH) and 
School of Medicine (JHSOM) 
o   Experience Description: During the first year of my Masters of Science degree 
at JHSPH, I conducted research in Dr. Phil Jordan’s lab. I wrote a literature 
review paper during this time on the ALT phenotype and cancer. In addition to 
my literature review, my primary research experience during this time included 
analyzing various pediatric glioma and osteosarcoma cell lines that exhibit the 
Alternative Lengthening of Telomeres (ALT) pathway for telomere elongation in 
the absence of telomerase. We collaborated with Dr. Allan Meeker’s lab at the 
JHSOM and surveyed for misexpressed meiotic genes involved in homologous 
recombination in the ALT phenotype.  
•   Experience Name: Independent Cancer Research Project at Anderson University’s 
Center for Cancer Research: The Cancer Scholar Program 
o   Total Hours: 950 
o   Dates: 8/2013-5/2014 
o   Organization Name: Anderson University, Center for Cancer Research 
o   Experience Description: During my fourth year at Anderson University, I was 
accepted into the Cancer Scholar Program at Anderson University’s Center for 
Cancer Research. During this time, I was responsible for sustaining the viability of 
my own cell line and conducting an independent research project. My project 
encompassed an assessment of the anti-proliferative and neurotoxic effects of extracts 
derived from the Clusia rosea tree on two morphologies of the rat 
pheochromocytoma-derived PC-12 cell line. I found a decrease in cell viability 
coinciding with an increase in extract concentration. I utilized the MTS photometric 
assay, trypan blue exclusion cell viability assay, fluctuations in pH of the cell media, 
and fluorescent staining to assess the effects of cell viability that the extracts had on 
this cell line. After my research was complete I composed a manuscript, presented a 
poster at a conference, and presented my work to the Biology Department of 
Anderson University. 	  
	  
•   	  Experience Name: Research internship, Dr. Sandra McAllister’s cancer research lab 
o   Total Hours: 112 
o   Dates: 12/10/2013 – 12/24-2013 
o   Organization Name: Harvard Medical School, Boston Children’s Hospital: 
Hematology Division  
o   Experience Description: During	  my	  internship	  at	  Dr.	  Sandra	  McAllister's	  lab,	  I	  
worked	  adjacent	  to	  renowned	  researchers	  on	  various	  cancer	  research	  projects.	  The	  
lab	  is	  part	  of	  Longwood	  Medical	  Center	  in	  Boston,	  MA,	  and	  is	  affiliated	  with	  
numerous	  surrounding	  institutions.	  During	  my	  stay,	  I	  performed	  tissue	  culturing,	  
immunohistochemistry,	  fluorescent	  microscopy,	  flux	  cytometry,	  attended	  meetings	  
with	  researchers,	  surgical	  grand	  rounds,	  a	  seminar	  at	  the	  Broad	  Institute,	  a	  seminar	  
at	  the	  Dana-­‐Farber	  Cancer	  Institute	  (DFCI),	  a	  seminar	  at	  Harvard	  Medical	  School,	  and	  
shadowed	  a	  physician	  at	  the	  DFCI. 
 
•   Experience Name: Cadaver Lab Experience 
o   Total Hours: 105 
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o   Dates: 5/2013 - 8/2013 & 1/2014 - 5/2014 
o   Organization Name: Anderson University, Cadaver Lab 
o   Experience Description: I began dissecting in Anderson University's cadaver lab 
during the summer of 2013. I worked one-on-one with the lab supervisor to prepare 
new cadavers for classes being held during the fall semester. During the Spring of 
2014, I was one of three students chosen to participate in a one credit course working 
to prepare the cadavers for anatomy and physiology (A&P) classes. Part of this course 
required us to help instruct one A&P lab and answer questions regarding the 
dissections. We performed dissections of the cranium, vertebrae, kidneys, heart, 
lungs, musculoskeletal system, gastrointestinal system, etc. The most influential 
dissection I performed was of the sinus cavities in the face. 
 
•   Experience Name: Volunteer time at Anderson University’s Center for Cancer Research 
o   Total Hours: 550  
o   Dates: 1/2013-8/2013 and 8/2014 – 5/2015 
o   Organization Name: Anderson University 
o   Experience Description: In the beginning of my journey at Anderson University's 
Center for Cancer Research, I began shadowing the current research students and 
learning cell culture techniques. During this time, I learned a variety of common 
techniques used in a sterile tissue culture lab. I received training on: Sterile technique, 
cell density assessment, dilution factors for media, plating cells for experiments, 
splitting/feeding cells, operating a fluorescent microscope, and operating a 
spectrophotometer. During the summer of that year, I maintained a cell line on my 
own and practiced procedures relevant to my future research project.  
§   During my final year at Anderson University, I helped the new cancer scholar 
students organize their projects, taught them tissue culture protocol, and 





•   Experience Name: Nurses Assistant/Monitor Tech/Unit Secretary, Neuro ICU 
o   Total Hours: ~1300 
o   Dates: 05/2013 – 06/2015 
o   Organization Name: AnMed Health 
o   Experience Description:  
§   When I was hired as a Certified Nurse’s Assistant (CNA) on the Neuro 
Intensive Care/ Telemetry Unit in May of 2013, I promptly acquired two 
separate certifications through the Nursing Staff Development Department 
of AnMed Health in July of 2013: one for a Monitor Tech (MT) and 
another for Unit Secretary (US). My MT job duties include monitoring 
ECG rhythms of patients in Neuro ICU and Telemetry (16 patient beds 
total). My US job duties include entering orders for physicians in AnMed's 
electronic ordering system, and putting together/maintaining charts. My 
CNA job duties include aiding basic needs for patients such as feeding, 
bathing, etc. In any given shift, I fill all 3 positions. 
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•   Experience Name: Shadowing Physicians at Spartanburg Regional Hospital 
o   Total Hours: 85 
o   Dates: 5/2013 – 8/2013 
o   Organization Name: Spartanburg Regional Hospital 
o   Experience Description: During my shadowing experience, I spent time 
observing multiple specialties of physicians. I feel as if this gave me a firm 
understanding of where each specialty fits in among the hospital system. Each 
specialty has something unique to offer during a patient’s course of treatment. 
The specialties I spent time shadowing included: ER physician, Trauma Surgeon, 
Neurosurgeon, Interventional Radiologist, Family Medicine Physician, 
Cardiothoracic Surgeon, and an Orthopedic Surgeon. Through spending time with 
both physicians on the forefront and those behind the scenes, I developed a strong 
grasp of the concepts surrounding how patients are displaced through a health 
care system. 
 
•   Experience Name: CNA state certification: 40 hours clinical/40 hours classroom 
o   Total Hours: 80 
o   Dates: 2/2013-4/2013 
o   Organization Name: Magnolia Place 
o   Experience Description: The 40 hours of clinical experience included cleaning, 
transporting, socializing with and feeding residents among other things. This was 
done in a primary care facility for the elderly. Many of the patients were total 
care, and had numerous cognitive or functional impairments. I learned a lot about 
alternative facilities of care for debilitations that are specific to these forms of 
care. The classroom sessions were primarily aimed at basic functionality of a 
healthcare system. We covered topics such as HIPAA regulations, workplace 




•   Experience Name: Student Assembly: Departmental Representative for the Department 
of Biochemistry and Molecular Biology  
o   Dates: 8/2016-6/2017 
o   Organization Name: Johns Hopkins School of Public Health Student Assembly  
o   Experience Description: During my time with JHSPH Student Assembly, I 
helped to build a stronger connection between the student population and our 
department. I was also a member of two committees within Student Assembly: 
Public Health Promotion and Quality of Life. I was involved in bridging the gap 
between the student and faculty populations by helping orchestrate student/faculty 
events and build a safe space for students with psychological struggles. I helped 
organize a week of activities for students to increase their quality of life during 
exams. I was also involved in helping to set up events that helped to build a 
stronger relationship between the Baltimore community and JHSPH by 
communicating issues such as domestic violence and vaccine communication 
awareness.  
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•   Experience Name: Member of the JHSPH BMB departmental events planning 
committee 
o   Dates: 8/2016-6/2017 
o   Organization Name: The Johns Hopkins School of Public Health, Department of 
Biochemistry and Molecular Biology  
o   Experience Description: During my time on this committee, I helped to 
orchestrate events such as:  
§   The incoming PhD/MHS Students Orientation Picnic  
§   The Departmental December Holliday Party  
§   Monthly Hump-Day Happy Hours hosted during the first Wednesday of 
every month  
o   In addition, I helped in making the decision for a logo for our departmental 
jackets, t-shirts, hoodies, etc.  
•   Experience Name: Vice President of Anderson University’s Science Club 
o   Total Hours: 75 
o   Dates: 08/2014 – 05/2015 
o   Organization Name: Anderson University 
o   Experience Description: I was elected to be the Vice President of Anderson 
University's Science Club in April of 2014 to fill the position beginning in August 
of that same year. By accepting this position, I am responsibility for providing 
food for about 70 science club members at our meetings once a month. I also 
collaborate with our club president to recruit presenters for our meetings. Because 
the science club population encompasses individuals interested in various fields of 
Biology and medicine, finding qualified individuals to present at our meeting has 
taught me what is valuable to these other fields. I have learned more about what is 
going on in our Biology department, and what opportunities are available. 
 
•   Experience Name: Sophomore Class President & Chairman of Student Relations 
o   Total Hours: 400 
o   Dates: 08/2010 – 05/2012 
o   Organization Name: Anderson University Student Government Association 
o   Experience Description: I became involved with Anderson University's Student 
Government during my freshmen year. I was elected as the Chairman of Student 
Relations for that year as well as the next. During my second year, I was elected 
as Sophomore Class President. Being a part of student government allowed me to 
attend retreats where I worked on my leadership skills, be part of the decision 
making for changes to our campus polices and facilities, and work symbiotically 
with the faculty to collaborate with the students regarding matters of institutional 
efficiency. My most influential duty was to create an AU Gold Card, which 





•   Experience Name: Helped to build and publish an ebook of tissue culture protocols for 
Anderson University’s Center for Cancer Research.  
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o   Total Hours: 250 
o   Dates: 08/2014-05/2015 
o   Organization Name: Anderson University Center for Cancer Research  
o   Experience Description: During this project, two other students and myself 
received a grant from Anderson University’s Mobile Learning Initiative program 
to build an ebook of tissue culture protocols that will be built into the cancer 
scholar program for years to come. Our protocols include splitting cells, feeding 
cells, trypsonizing cells, thawing cells, hemocytometer count to determine cell 
density, plating cells in 96-well plates, sterile technique, and an introduction to all 
the equipment we use in a cell culture lab including its purpose. Through this 
project, I have solidified my understanding of cell culture and have been able to 
participate in something that will benefit cancer scholar students for years to 
come.  
 
•   Experience Name: Volunteer time at Anderson University’s Center for Cancer Research 
(Also stated in “Research and Lab Experiences” Section of this document) 
o   Total Hours: 550  
o   Dates: 1/2013-8/2013 and 8/2014 – 5/2015 
o   Organization Name: Anderson University 
o   Experience Description: In the beginning of my journey at Anderson 
University's Center for Cancer Research, I began shadowing the current research 
students and learning cell culture techniques. During this time, I learned a variety 
of common techniques used in a sterile tissue culture lab. I received training on: 
Sterile technique, cell density assessment, dilution factors for media, plating cells 
for experiments, splitting/feeding cells, operating a fluorescent microscope, and 
operating a spectrophotometer. During the summer of that year, I maintained a 
cell line on my own and practiced procedures relevant to my future research 
project.  
§   During my final year at Anderson University, I helped the new cancer 
scholar students organize their projects, taught them tissue culture 
protocol, and participated in lab meetings with the current cancer scholars 
and their advisors.  
 
•   Experience Name: Helped to Orchestrate The Race For Gold Fundraiser 
o   Total Hours: 100 
o   Dates: 09/2012 
o   Organization Name: Race for the Gold 
o   Experience Description: During my interaction with the Race for Gold project, I 
helped contact local businesses to inquire about sponsorship for the race. We 
raised $3000 for Anderson University's Center for Cancer Research as a result, 
and this money went to fund materials and instruments for the center. Some of the 
money we raised went to funding our florescent microscope. I aided in advertising 
for the race by hanging posters around the University and in the community. 
During the awards ceremony at the race, I introduced the attending cancer 
survivors. Through volunteering for this fundraiser, I learned the logistics 
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•   Experience Name: Skydiving (Holder of an A-License) 
o   Total Hours: 450 
o   Dates: 09/2011 - present  
o   Organization Name: United States Parachute Association  
o   Experience Description: I obtained an A-license in the sport of skydiving 
through the United States Parachute Association in April of 2012, and actively 
skydive a few times a month. As of June 2015, I have 80 independent skydives. 
This license required a list of maneuvers that I had to complete on my own before 
I could obtain the license (e.g. back-flip and front-flip, dive 500 feet after and 
dock with an instructor, land within a given distance from a target, etc.). With this 
license, I can skydive without an instructor, pack and jump my own parachute, 
and participate in skydiving competitions. 
 
•   Experience Name: Trip to the Peruvian Amazon Rainforest 
o   Total Hours: 250 
o   Dates: 08/2012 – 12/2012 
o   Organization Name: Amazonia Expeditions 
o   Experience Description: As a part of a class taken during the fall semester of 
2012, I had the opportunity to attend a trip to Peru and experience the Amazon 
Rainforest as part of the laboratory credit for the course. This class focused on 
conservation efforts of the Peruvian Amazon Ecology. During our trip, we stayed 
in a hut located on the Tahuayo River, which is a tributary to the Amazon River. 
We spent half of our time at a research center that is located further down the 
Tahuayo. While we were here our group met with a Shaman in a local village, La 
Esparanza. A plant that the Shaman used as a medicine was the same plant I used 
in my Cancer Scholar research project. Our class also participated in numerous 
cultural activities, which included: making blow darts, attending a shaman 
ceremony, spending a night survivor camping, fishing for piranha, and various 
walks through the forest during the day and night. 
Presentations  
 
•   Experience Name: Presentation of research in Charleston, SC at SCAS 
o   Total Hours: 24 
o   Dates:  
o   Organization Name: South Carolina Academy of Science 
o   Experience Description: During this part of the research process, my partner and 
I presented a poster of our final product to a large congregation of scientists at the 
South Carolina Academy of Sciences. Our research project entailed treating pc-12 
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cancer cells and ASB-pancreatic cancer cells with plant extracts derived from the 
Clusia Rosea tree. This experience helped me better understand the details of the 
research projects that other colleges are conducting in my state. My partner and I 
received valuable feedback on our project from other researchers, which we 
helped to incorporated in to the next round of projects new students will conduct. 
Collaboration in research is one of its most valuable aspects. 
 
•   Experience Name: Presentation of research in Spartanburg, SC at ASB 
o   Total Hours: 8 
o   Dates: 04//2014 
o   Organization Name: Association of Southeastern Biologists 
o   Experience Description: During this presentation, my partner and I presented a 
poster at the Association of Southeastern Biologists annual meeting. We 
presented a poster of our research to a group of scientists. We participated in the 
exchange of information with the rest of the scientific community on a larger 
basis. We had the opportunity to compared our research to those doing similar 
research in the Southeastern United States. 
 
•   Experience Name: Presentation of research at Cancer Survivor Meeting 
o   Total Hours: 2 
o   Dates: 05//2014 
o   Organization Name: AnMed Health Cancer Center 
o   Experience Description: At this meeting, I presented to a group of cancer 
survivors of various types. My presentation consisted of the essential and easy to 
understand points of my full research project. During this experience, I practiced 
communicating with individuals that do not have a strong background in cancer 
biology. By answering questions in ways that made sense to the individuals, I 
effectively described the assumptions and conclusions of my research project, 




•   Experience Name: Dean’s List  
o   Dates: 8/2011 – 5/2015 
o   Organization Name: Anderson University 
o   Experience Description: I have made it to the Dean’s List of the university for 8 
consecutive semesters.  
 
•   Experience Name: Dabo’s All-In Team Foundation Grant 
o   Total Hours: 24 
o   Dates: 10/2014 
o   Organization Name: Dabo’s All In Team Foundation 
o   Experience Description: The Dabo's All In Team Foundation aims to supply 
funding to projects and events that increase the awareness of health issues. By 
writing a proposal, I helped Anderson University's (AU) Center for Cancer 
Research (CCR) apply for a grant through this program, and it was awarded to the 
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amount of $5,000. With this money, AU's CCR will be able to order supplies and 
necessary equipment to advance the quality of the research it conducts. This 
quality will be mirrored in the students it graduates. In the past, this award has 
helped fund a 96-well plate spectrophotometer and a -80°C freezer. By 
successfully fulfilling this task, I learned more about the process of applying for, 
and receiving, a grant. 
 
•   Experience Name: Cancer Scholar Award at University Convocation 
o   Total Hours: 4  
o   Dates: 05/2014 
o   Organization Name: Anderson University 
o   Experience Description: I received this award at Anderson University's Spring 
Convocation Ceremony. I was elected as a Cancer Scholar during the fall of 2013, 
and fulfilled my duties by accomplishing a yearlong research project at Anderson 
University's Center for Cancer Research. During the ceremony, I took a seat on 
stage with the rest of the faculty, staff, and other award recipients. The President 






***Transcripts available upon request *** 
 
Undergraduate: Anderson University (August 2010 - May 2015):  
•   Address: 316 Boulevard, Anderson, SC 29621 
•   Degree: B.S. Biology, Minor Chemistry 
•   Strong social science background (one class away from earning a minor in psychology) 
•   GPA: 3.61  
•   Honors: Cum Laude  
Graduate: Johns Hopkins School of Public Health (August 2015-present)  
•   Address: 615 N. Wolfe street, Baltimore, MD, 21231 
•   Degree: ScM (Masters of Science) Biochemistry and Molecular Biology  
 
  
